Latest technologies from Iowa State Universityhttp://isurftech.technologypublisher.comBe the first to know about the latest inventions and technologies available from Iowa State Universityen-USThu, 23 Nov 2017 06:28:44 GMTThu, 23 Nov 2017 06:28:44 GMThttp://blogs.law.harvard.edu/tech/rsssupport@inteum.comCopyright 2017, Iowa State UniversityPKC Delta Cleavage Site Peptide Inhibitor for Use in Research and Diagnosishttp://isurftech.technologypublisher.com/technology/19201Summary:
A researcher has developed a peptide inhibitor for the protein kinase C delta cleavage site that has utility as a research reagent and for the measurement of caspase-3 activity.

Description:
Oxidative stress and apoptosis are considered important common mediators of many diseases, including Alzheimer’s and Parkinson’s diseases.  Caspase-3 has been shown to activate protein kinase C delta (PKCδ) through proteolytic cleavage, leading to PKCδ-mediated apoptosis of cultured neuronal cells. Researchers at ISU have developed an irreversible and competitive peptide inhibitor of the PKCδ cleavage site that demonstrates potent anti-apoptotic effects.  This cell permeable inhibitor is more potent than the commonly used inhibitor Z-DEVD-fmk and has been shown to block caspase-3-dependent activation of PKCδ and DNA fragmentation in neuronal cell culture; neuronal protection has been demonstrated using Parkinson’s disease models.  Because of its efficacy, this inhibitor may have utility as a reagent for investigating apoptosis as well as for measuring caspase-3 activity through competitive inhibition assays.  This technology is available for licensing in the areas of research reagents and apoptosis diagnostics.

Advantage:
• The peptide inhibitor is much more potent than other known caspase-3 inhibitors
• Relatively selective
• Demonstrated to be effective as an experimental neuroprotective agent.

Application:
Research (experimental reagent for apoptosis and oxidative cell stress research) and Diagnostic (measurement of caspase-3 activity)

References:
1: “A novel PKC delta (PKCδ) inhibitor protects against oxidative stress-induced apoptotic cell death in neurodegenerative disease models”, Anumantha G. Kanthasamy, Claivarathan Latchoumycandane, Siddharth Kaul, Vellareddy Anantharam and Arti Kanthasamy.  Presented at the Experimental Biology (April 2-6, 2005) and the XXXV International Congress on Physiological Sciences, (March 31-April 5, 2005), San Diego, CA.

2: “A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson's disease models”, V. Anantharam , D. Zhang , C. Latchoumycandane, H. Jin, S. Kaul, and A. Kanthasamy, 2006, Free Radical Biol. Med. 41:1578-1589.

Group:
This technology is related to ISURF #3411: Parkinson’s Disease - Dual Beneficial Effect of PKC Delta Inhibitors for Treatment

Stage0.png
Development Stage:
With an IC50 of 6 µM, the peptide inhibitor has been demonstrated to be three-fold more potent than the classical used caspase-3 inhibitor Z-DEVD-fmk, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>
Tue, 05 May 2015 10:39:04 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/192013172Tue, 21 Nov 2017 07:45:30 GMTSummary:

]]>Description:

]]>Advantage:]]>Application:

]]>References:1: “A novel PKC delta (PKCδ) inhibitor protects against oxidative stress-induced apoptotic cell death in neurodegenerative disease models”, Anumantha G. Kanthasamy, Claivarathan Latchoumycandane, Siddharth Kaul, Vellareddy Anantharam and Arti Kanthasamy.  Presented at the Experimental Biology (April 2-6, 2005) and the XXXV International Congress on Physiological Sciences, (March 31-April 5, 2005), San Diego, CA.

2: “A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson's disease models”, V. Anantharam , D. Zhang , C. Latchoumycandane, H. Jin, S. Kaul, and A. Kanthasamy, 2006, Free Radical Biol. Med. 41:1578-1589.

]]>Group:ISURF #3411: Parkinson’s Disease - Dual Beneficial Effect of PKC Delta Inhibitors for Treatment

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life Sciences| Veterinary MedicineMethods and Compositions for Inhibiting PKC Delta Cleavage for Treatment and Prevention of Neurodegeneration and ApoptosisUtilityUnited States7,632,81911/262,67710/31/200512/15/200910/25/20275/7/201511/13/2017FalseParkinson’s Disease - Dual Beneficial Effect of PKC Delta Inhibitors for Treatmenthttp://isurftech.technologypublisher.com/technology/19200Description:
Parkinson’s disease (PD) is a neurodegenerative disorder that affects over six million people worldwide.  Its most prominent symptoms, which result from the death of dopamine-producing cells, are related to movement, and include tremors, difficulty with walking, rigidity, and slow movement.  Current treatments tend to merely control symptoms of Parkinson’s disease, while future therapeutic goals include the development of neuroprotective agents that slow disease progression or may even result in curing it.
ISU researchers have developed a portfolio of technologies with potential as neuroprotective agents for the treatment of PD and as targets for the development of novel therapies.  This technology suite includes ISURF #s 3172, 3411, and 3728.   ISURF #3172 is an irreversible and competitive peptide inhibitor of the protein kinase C δ (PKCδ) cleavage site that demonstrates potent anti-apoptotic effects.  This cell permeable inhibitor is more potent than the commonly used inhibitor Z-DEVD-fmk and has been shown to block caspase-3-dependent activation of PKCδ and DNA fragmentation in neuronal cell culture; neuronal protection has been demonstrated using Parkinson’s disease models.  ISURF #3411 describes effects of a PKCδ inhibitor which increases dopamine synthesis and confers neuroprotective effects in PD animal models.  ISURF #3728 includes the design and synthesis of analogs of the inhibitor with simpler structures and increased activity that have been demonstrated to confer neuroprotection in cell culture models of PD.

Advantage:
• Neuroprotective in PD cell culture and animal models

Application:
Pharmaceutical development

References:
1: “A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson's disease models”, V. Anantharam , D. Zhang , C. Latchoumycandane, H. Jin, S. Kaul, and A. Kanthasamy, 2006, Free Radical Biol. Med. 41:1578-1589.

2: “Protein Kinase Cδ Negatively Regulates Tyrosine Hydroxylase Activity and Dopamine Synthesis by Enhancing Protein Phosphatase-2A Activity in Dopaminergic Neurons”, D. Zhang, A. Kanthasamy, Y. Yang, V. Anantharam, and A. Kanthasamy, 2007, J. Neurosci. 27:5349-5362.

3: “Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: Relevance to oxidative stress and neuroinflammation in Parkinson's disease”, A. Kanthasamy, H. Jin, S. Mehrotra, R. Mishra, A. Kanthasamy, and A. Rana. 2010. NeuroToxicology 31:555-561.

Group:
This technology is related to ISURF #3172: PKC Delta Cleavage Site Peptide Inhibitor for Use in Research and Diagnosis

Stage0.png

Desc0000.png

]]>Tue, 05 May 2015 10:39:04 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/192003411Tue, 21 Nov 2017 07:45:30 GMTDescription:
ISU researchers have developed a portfolio of technologies with potential as neuroprotective agents for the treatment of PD and as targets for the development of novel therapies.  This technology suite includes ISURF #s 3172, 3411, and 3728.   ISURF #3172 is an irreversible and competitive peptide inhibitor of the protein kinase C δ (PKCδ) cleavage site that demonstrates potent anti-apoptotic effects.  This cell permeable inhibitor is more potent than the commonly used inhibitor Z-DEVD-fmk and has been shown to block caspase-3-dependent activation of PKCδ and DNA fragmentation in neuronal cell culture; neuronal protection has been demonstrated using Parkinson’s disease models.  ISURF #3411 describes effects of a PKCδ inhibitor which increases dopamine synthesis and confers neuroprotective effects in PD animal models.  ISURF #3728 includes the design and synthesis of analogs of the inhibitor with simpler structures and increased activity that have been demonstrated to confer neuroprotection in cell culture models of PD.

]]>Advantage:Application:

]]>References:1: “A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson's disease models”, V. Anantharam , D. Zhang , C. Latchoumycandane, H. Jin, S. Kaul, and A. Kanthasamy, 2006, Free Radical Biol. Med. 41:1578-1589.

2: “Protein Kinase Cδ Negatively Regulates Tyrosine Hydroxylase Activity and Dopamine Synthesis by Enhancing Protein Phosphatase-2A Activity in Dopaminergic Neurons”, D. Zhang, A. Kanthasamy, Y. Yang, V. Anantharam, and A. Kanthasamy, 2007, J. Neurosci. 27:5349-5362.

3: “Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: Relevance to oxidative stress and neuroinflammation in Parkinson's disease”, A. Kanthasamy, H. Jin, S. Mehrotra, R. Mishra, A. Kanthasamy, and A. Rana. 2010. NeuroToxicology 31:555-561.

]]>Group:ISURF #3172: PKC Delta Cleavage Site Peptide Inhibitor for Use in Research and Diagnosis

]]>Stage0.pngDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesDual Beneficial Effect of Dopamine Enhancing and Neuroprotective Actions of PKC Delta Inhibitors for Treatment of Parkinson's DiseaseUtilityUnited States8,653,02311/479,1736/30/20062/18/20148/25/20315/7/201511/13/2017FalseNovel Protein Synthases for the Production of Bi-Functional Fatty Acidshttp://isurftech.technologypublisher.com/technology/21833Summary:
ISU researchers have developed biocatalysts that make bi-functionalized molecules (fatty acids) and a recombinant bacterial expression system.

Description:
Fatty acids normally synthesized in biological systems have only one functional group, carboxylic acid, which is found at the alpha end of the molecule. Bi-functional fatty acids, where there is also a functional group at the omega end of the molecule, are desirable for industrial applications, but are produced by only a few natural systems and at levels that are too low for practical replacement of petroleum-based sources of monomers.  Approaches that enable larger scale production of bi-functional fatty acids will help drive the use of bio-based chemicals. The technology addresses the need for efficient production of bi-functionalized fatty acids that can be used as precursors for the bio-based production of polymers, surfactants, and various specialty chemicals and has the potential to serve as the basis of development of tailored enzymes that are designed to incorporate different functionalities into fatty acids to produce a range of bi-functionalized precursor molecules.

Advantage:
• Produces bi-functional fatty acids
• Replacement for petroleum-based sources of monomers
• Serves a precursor for a wide variety of specialty chemicals, polymers, and surfactants
• Very lucrative market

Application:
Bio-based chemicals, Specialty chemicals

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Fri, 29 Apr 2016 12:41:52 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/218334083Wed, 15 Nov 2017 07:15:24 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:Bio-based chemicals, Specialty chemicalsPatent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngCraigForneyCommercialization Manager, Chemistry and Materials Sciencesceforney@iastate.edu515-294-4740Materials and Methods for Characterizing and Using KASIII for Production of Bi-Functional Fatty AcidsUtilityUnited States9,809,80414/762,7917/29/201511/7/20177/29/203511/15/201711/21/2017FalseMagnetic two-way valves for paper based microfluidics: pathway for multi-step assayshttp://isurftech.technologypublisher.com/technology/26576Summary:
ISU researchers developed a paper-fluidic valve that can reversibly switch fluid delivery into multiple channels with controlled volume and/or frequency. In terms of electric circuit equivalence, this valve is akin to a transistor or an SPDT relay, hence enables programmable fluid delivery.

Stage1.png
Development Stage:

Description:
Point-of-care diagnostics are an area of emerging interest for many health-care applications, particularly in-home or personalized care. Paper microfluidic lab-on-a-chip technologies have attracted a lot of attention in this area due to their low cost, with the assays often being disposable. Switching and gating mechanisms that are possible in many non-paper lab-on-a-chip technologies are not possible in the paper based analogues however, so new solutions have to be developed in order for functionality of these diagnostic tests to be similar to the more expensive tests. In paper microfluidics, the development of smart, reversible, and versatile switches is critical for the regulation of fluid flow across multiple channels.  Common limitations of current switches include long response times, limited switching capabilities, and irreversibility. A gating mechanism that is reversible, quick, and versatile is therefore interesting. To respond to this market need Iowa State University researchers have developed a paper-based microfluidic valve, capable of being switched between multiple channels in a reversible fashion.

Advantage:
• Reversible
• Cheap
• Fast acting
• Multichanneled
• Programmable
• Power-free

Application:
Microfluidics, sample preparation, purification, separation, diagnostics, ordering fluids schemes

Desc0000.png

]]>Fri, 10 Nov 2017 11:38:34 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/265764675Mon, 13 Nov 2017 10:27:24 GMTSummary:

]]>Stage1.pngDevelopment Stage:Description:

]]>Advantage:

]]>Application:]]>Desc0000.pngMarkJuettenAssociate Commercialization Manager, Chemistrymjuetten@iastate.eduFalseMachine for Computing Casual Inference from Time Series Datahttp://isurftech.technologypublisher.com/technology/26331Summary:
Iowa State University researchers have developed a novel algorithm approach for computing causal interaction from time series data. The proposed approach will help determine which time series data will cause or influence which other time series data, given two or more-time series data.

Stage1.png
Development Stage:

Description:
The detection between cause and effect (causality) has long been a question in many scientific area. There are various theories developed so far, but they failed to give the causal structure in dynamic systems. Besides, none of these definitions is capable of differentiation of direct and indirect influence, and identification of links from the system.
Iowa State University researchers provided a new definition of information transfer between the states of a dynamic system, and the definition captures the intuitions of information transfer, like transfer asymmetry, zero transfer and information conservation. Furthermore, this measure clearly distinguish between direct and indirect influence.
The researchers has demonstrated that how this information measure can be used to characterize influence in real world networks. For example, analyzing time-series data of two different stocks it will be possible to determine which stock is causing or influencing the other stock i.e., the direction and degree of influence can be determined using our proposed approach. Similarly, in application involving health care and medicine discovery it will be possible to determine which genes among millions of genes in the gene regulatory network is most responsible for causing genetic disorder and hence disease.

Advantage:
• Captures the true causal structure in dynamic system
• Distinguish between direct and indirect influence
• Demonstration of the approach through stock prices analysis

Application:
This novel algorithm approach will find application in various filed where the primary goal is to infer causal interaction between two or more quantities, such as stock market, health care, medicine discovery and etc.

Desc0000.png

]]>Wed, 27 Sep 2017 10:43:35 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/263314607Mon, 13 Nov 2017 10:27:06 GMTSummary:

]]>Stage1.png

]]>Description:Iowa State University researchers provided a new definition of information transfer between the states of a dynamic system, and the definition captures the intuitions of information transfer, like transfer asymmetry, zero transfer and information conservation. Furthermore, this measure clearly distinguish between direct and indirect influence.
The researchers has demonstrated that how this information measure can be used to characterize influence in real world networks. For example, analyzing time-series data of two different stocks it will be possible to determine which stock is causing or influencing the other stock i.e., the direction and degree of influence can be determined using our proposed approach. Similarly, in application involving health care and medicine discovery it will be possible to determine which genes among millions of genes in the gene regulatory network is most responsible for causing genetic disorder and hence disease.

]]>Advantage:

]]>Application:This novel algorithm approach will find application in various filed where the primary goal is to infer causal interaction between two or more quantities, such as stock market, health care, medicine discovery and etc.Desc0000.pngJayBjerkeCommercialization Manager, Engineeringjbjerke@mail.iastate.edu515-294-4740FalseProbiotic treatment of gut inflammationhttp://isurftech.technologypublisher.com/technology/25990Summary:
A screening methodology to identify potentially beneficial probiotic strains and strains identified using such methodology.

Stage1.png
Development Stage:

Description:
Probiotics are live organisms that confer beneficial health effects to human and animals. The use of probiotics to treat gut inflammation is widespread and has been ongoing for decades. Critically, none of the probiotics used for this purpose have been approved by any governmental regulatory body principally because there is no defined mechanism by which they work. This prevents any approval by the FDA.
 
ISU researchers have discovered new biochemical properties in some probiotics that would explain how some of them work to reduce gut inflammation. In addition, they have developed a screening method to identify potentially beneficial probiotic strains with the desired biochemical properties. Use of the screening methodology yielded specific strains that are available for licensing.

Advantage:
• New discovery of a microbial endocrinology-based mechanism
• Screening methodology to identify potentially beneficial probiotic strains.
• Probiotic strains available for licensing.

Group:
This technology is related to ISURF 4568: Neurotransmitter transport in probiotics

Desc0000.png

]]>Wed, 09 Aug 2017 11:53:20 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/259904644Mon, 13 Nov 2017 10:26:53 GMTSummary:

]]>Stage1.png

]]>Description: 
ISU researchers have discovered new biochemical properties in some probiotics that would explain how some of them work to reduce gut inflammation. In addition, they have developed a screening method to identify potentially beneficial probiotic strains with the desired biochemical properties. Use of the screening methodology yielded specific strains that are available for licensing.

]]>Advantage:]]>Group:ISURF 4568: Neurotransmitter transport in probiotics

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life Sciences| Veterinary MedicineFalseQuadruple Butterfly Coil (QBC)http://isurftech.technologypublisher.com/technology/26355

Summary:
Iowa State University researchers have developed a novel coil, namely Quadruple Butterfly Coil (QBC). This device has improved significant higher focality over the commercial Figure of Eight (FOE) coils with decreased stimulated area in brain. Model simulation results indicated that QBC stimulates a localized area of the brain, which minimized the stimulation of surrounding neural networks.

Stage3.png
Development Stage:

Description:
Transcranial Magnetic Stimulation (TMS) is a widely used technique for the investigation of stimulation responses of the brain which has proven to have therapeutic effects for neurological disorders such as traumatic brain injury, Parkinson’s disease and post-traumatic stress disorder (PTSD). There have been many coils designed in the last twenty years due to TMS’ popularity, but no coils have shown significant improvement in focality over the commercial Figure of Eight (FOE) coils, while maintaining the field intensity required to stimulate at the depth of the surface of the brain.

Iowa State University researchers designed a new coil, Quadruple Butterfly Coil (QBC) with an improved double coil with two sets of coils. This new coil achieved a finer resolution for stimulation, with decreased stimulation volume over the cortex, while without deeper brain stimulation. QBC has been compared with commercial FOE coils using 50 anatomically realistic heterogeneous MRI derived head models, and results shows QBC has a significant improvement in focality over FOE with decreased stimulation area by approximately 1/3.

Lately, QBC performance for the application of Schizophrenic patients has been simulated at Magnetics Research Group at ISU. Preliminary results demonstrated the QBC provides a lightly weaker field, but has more focal over the FOE coils.  Specifically, the volume stimulated above 50% the local maximum was 30x greater in the FOE.

Advantage:
• Significantly higher focus of stimulation over the Figure of Eight (FOE) coils
• Smaller stimulated area by 1/3, with minimized stimulation of surrounding neural networks
• Decrease in Maximum induced E-field by about 50V/m
• QBC performance has been demonstrated via simulation for the application of Schizophrenic patients

Application:
This first major version of Quadruple Butterfly Coil (QBC) device can be used in neuromodulation market to improve therapeutic effects for neurological disorders patients.

References:
Transcranial Magnetic Stimulation-coil design with improved focality

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 04 Oct 2017 12:27:12 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/263554566Mon, 13 Nov 2017 10:26:36 GMTSummary:Iowa State University researchers have developed a novel coil, namely Quadruple Butterfly Coil (QBC). This device has improved significant higher focality over the commercial Figure of Eight (FOE) coils with decreased stimulated area in brain. Model simulation results indicated that QBC stimulates a localized area of the brain, which minimized the stimulation of surrounding neural networks.

]]>Stage3.pngDevelopment Stage:Description:Transcranial Magnetic Stimulation (TMS) is a widely used technique for the investigation of stimulation responses of the brain which has proven to have therapeutic effects for neurological disorders such as traumatic brain injury, Parkinson’s disease and post-traumatic stress disorder (PTSD). There have been many coils designed in the last twenty years due to TMS’ popularity, but no coils have shown significant improvement in focality over the commercial Figure of Eight (FOE) coils, while maintaining the field intensity required to stimulate at the depth of the surface of the brain.

Iowa State University researchers designed a new coil, Quadruple Butterfly Coil (QBC) with an improved double coil with two sets of coils. This new coil achieved a finer resolution for stimulation, with decreased stimulation volume over the cortex, while without deeper brain stimulation. QBC has been compared with commercial FOE coils using 50 anatomically realistic heterogeneous MRI derived head models, and results shows QBC has a significant improvement in focality over FOE with decreased stimulation area by approximately 1/3.

Lately, QBC performance for the application of Schizophrenic patients has been simulated at Magnetics Research Group at ISU. Preliminary results demonstrated the QBC provides a lightly weaker field, but has more focal over the FOE coils.  Specifically, the volume stimulated above 50% the local maximum was 30x greater in the FOE.

]]>Advantage:Significantly higher focus of stimulation over the Figure of Eight (FOE) coils]]>Smaller stimulated area by 1/3, with minimized stimulation of surrounding neural networks]]>Decrease in Maximum induced E-field by about 50V/m]]>QBC performance has been demonstrated via simulation for the application of Schizophrenic patients

]]>Application:

]]>References:Transcranial Magnetic Stimulation-coil design with improved focality

]]>Patent:Patent(s) applied forDesc0000.pngJayBjerkeCommercialization Manager, Engineeringjbjerke@mail.iastate.edu515-294-4740FalseHaemophilus Influenzae Immunogenhttp://isurftech.technologypublisher.com/technology/25665Summary:
A powerful antigenic protein for the development of a vaccine against Nontypeable Haemophilus Influenzae

Stage1.png
Development Stage:

Description:
Nontypeable Haemophilus Influenzae (NTHI) is a significant respiratory pathogen associated with millions of yearly middle ear infections in young children and with many cases of pneumonia in the elderly. Currently, there is no efficacious vaccine against Nontypeable Haemophilus Influenzae. By comparing children prone to ear infections with non-prone children, the ISU contributors discovered that non-prone children differed from prone children by having a strong antibody response against a specific Nontypeable Haemophilus Influenzae protein. This discovery with its subsequent validation could be the basis for the development of an effective commercial vaccine against the pathogen.

Advantage:
• May enable the first commercial Nontypeable Haemophilus Influenzae vaccine
• Strong in vivo protection in mice againts many strains
• Highly conserved protein immunogen

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 19 Jul 2017 12:25:39 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/256654475Mon, 13 Nov 2017 10:26:33 GMTSummary:

]]>Stage1.png

]]>Description:

]]>Advantage:

]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalsePotato tuber yield enhancementhttp://isurftech.technologypublisher.com/technology/25635Summary:
Inhibition of two potato genes can be used to produce plants with greater tuber yields without affecting plant growth.

Stage1.png
Development Stage:

Description:
Researchers from Iowa State University and the Indian Institute of Science Education and Research have jointly demonstrated increased tuber yields in potato by inhibiting the potato genes StBEL11 and StBEL29.
Potato BEL1-like genes encode transcription factors that work in tandem with KNOTTED1-types to regulate the expression of many genes. Potato StBEL5 functions as a long-distance mRNA signal that is transcribed in leaves and moves into roots and stolons to stimulate growth. StBEL11 and StBEL29 are most closely related to StBEL5, and like StBel5 function as mobile RNAs.  However, over-expression of StBEL11 and StBEL29 produces plants with suppressed tuberization, in contrast to StBel5 which enhances tuberization. RNA suppression lines of StBEL11 and StBEL29 exhibit enhanced overall tuber yield with no effect on shoot growth. Thus, RNA suppression of StBEL11 and StBEL29 can be used to produce plants with greater overall tuber yields without affecting overall plant growth.

Advantage:
• Increased yield.
• Demonstrated inhibition using RNA suppresion
• Potential for inhibition by gene editing
• RNAi technology already in use commercially for potatoes

Application:
Potato Crop Improvement

References:
1. The Mobile RNAs, StBEL11 and StBEL29, Suppress Growth of Tubers in Potato.  Plant Mol Biol. 2017 Apr;93(6):563-578. doi: 10.1007/s11103-016-0582-4. Epub 2017 Jan 13.  Ghate TH,  Sharma P,  Kondhare KR,  Hannapel DJ and Banerjee AK.

2. Review: Multiple Mobile mRNAs Signals Regulate Tuber Development in Potato Plants (Basel). 2017 Feb 10;6(1). pii: E8. doi: 10.3390/plants6010008. David H. Hannapel and Anjan K. Banerjee

Patent:
Patent(s) applied for


Group:
This technology is related to ISURF 3056: Enhanced Plant Growth through Mobile RNA Signals

Desc0000.png

]]>Wed, 12 Jul 2017 14:39:14 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/256354587Mon, 13 Nov 2017 10:26:30 GMTSummary:

]]>Stage1.png

]]>Description:Potato BEL1-like genes encode transcription factors that work in tandem with KNOTTED1-types to regulate the expression of many genes. Potato StBEL5 functions as a long-distance mRNA signal that is transcribed in leaves and moves into roots and stolons to stimulate growth. StBEL11 and StBEL29 are most closely related to StBEL5, and like StBel5 function as mobile RNAs.  However, over-expression of StBEL11 and StBEL29 produces plants with suppressed tuberization, in contrast to StBel5 which enhances tuberization. RNA suppression lines of StBEL11 and StBEL29 exhibit enhanced overall tuber yield with no effect on shoot growth. Thus, RNA suppression of StBEL11 and StBEL29 can be used to produce plants with greater overall tuber yields without affecting overall plant growth.

]]>Advantage:

]]>Application:

]]>References:1. The Mobile RNAs, StBEL11 and StBEL29, Suppress Growth of Tubers in Potato.  Plant Mol Biol. 2017 Apr;93(6):563-578. doi: 10.1007/s11103-016-0582-4. Epub 2017 Jan 13.  Ghate TH,  Sharma P,  Kondhare KR,  Hannapel DJ and Banerjee AK.

2. Review: Multiple Mobile mRNAs Signals Regulate Tuber Development in Potato Plants (Basel). 2017 Feb 10;6(1). pii: E8. doi: 10.3390/plants6010008. David H. Hannapel and Anjan K. Banerjee]]>Patent:Patent(s) applied forGroup:ISURF 3056: Enhanced Plant Growth through Mobile RNA Signals

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseCanine intestinal stem cells for drug development, precision and regenerative medicinehttp://isurftech.technologypublisher.com/technology/25529Summary:
Canine intestinal cell lines (i.e. enteroids) cultures for basic and applied medical research.

Stage2.png
Development Stage:

Description:
Canine intestinal cell lines (i.e. enteroids) cultures for basic and applied medical research. The enteroids were developed with the goal enable the use of stem cells from dogs that spontaneously develop diseases of the gastrointestinal tract to improve the predictability of preclinical models used for gastrointestinal research. Further, the researchers envision a wide range of applications using dog enteroids including the study of the biology of intestinal bowel disease and intestinal cancer, screening of potential therapeutic drugs, optimization of individualized medicine, and transplantation of enteroids in canine clinical trials.

Advantage:
• Extensive characterization of cell lines in the organoids by immunohistochemistry, RT-PCR, and RNAscope
• Proof of genetic stability over passages and proof of canine origin of cells
• Archive of enteroids from different intestinal sites of dogs and from dogs diagnosed with intestinal disease (inherited diseases, inflammatory bowel disease, cancer)

Application:
Biomedical research and therapeutics.

Intellectual Property:
Tangible Material

Desc0000.png

]]>Wed, 21 Jun 2017 14:22:33 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/255294641Mon, 13 Nov 2017 10:26:21 GMTSummary:

]]>Stage2.png

]]>Description:

]]>Advantage:

]]>Application:

]]>Intellectual Property:Tangible MaterialDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Life Sciences| Veterinary MedicineFalseGene controlling spontaneous haploid genome doubling in maizehttp://isurftech.technologypublisher.com/technology/25528Summary:
A specific mutation in a maize gene is associated with enhanced spontaneous haploid genome doubling.

Stage2.png
Development Stage:

Description:
To produce commercial hybrid maize one inbred corn line is crossed with a different inbred line. Using traditional breeding, it takes 5 to 8 generations to develop one inbred line. Doubled haploid (DH) technology typically produces inbred corn lines in a couple of generations, since the offspring contain only a single genome instead of two.  Inducer lines are used as pollinators in the DH approach.  DH has been widely adopted by maize breeders.  Artificial haploid genome doubling, which commonly involves toxic and costly chemicals, is a major challenge in the DH process. ISU researchers have identified a a specific mutational change in maize which is associated with the spontaneous haploid doubling effect. This discovery opens the way for the rapid introduction of the mutation in elite germplasm by either marker assisted breeding or gene editing.

Advantage:
• Mutation that is easily transferable
• Avoidance of costly toxic chemical to double haploid genomes

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 21 Jun 2017 14:18:25 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/255284636Mon, 13 Nov 2017 10:26:20 GMTSummary:

]]>Stage2.png

]]>Description:

]]>Advantage:]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseUse of the XA1 rice gene to confer broad Xanthomonas resistance in plantshttp://isurftech.technologypublisher.com/technology/25527Summary:
The Xa1 gene induces resistance to all or nearly all TAL effectors in certain crops thus providing with a new approach to combat most crop diseases induced by Xanthomonas.

Stage2.png
Development Stage:

Description:
By unmasking the suppressive function of bacterial pseudogenes, the researchers discovered hat Xa1, an NBS-LRR type disease resistance gene in rice, can recognize all test TAL effector genes and confer disease resistance to those pathogenic bacteria that contain such TALE effector genes. Several crop diseases, such as wheat blight, citrus canker, cotton blight, etc. are caused by Xanthomonas bacteria that harbor multiple copies of TAL effector genes but not suppressor pseudogene. Therefore, Xa1 and its derivatives can be used as broad spectrum disease-resistance genes.

Advantage:
• Native rice gene.
• Wheat plants available for evaluation.
• Predicted broad resistance to Xanthomonas in most plants.

References:
Interfering TAL effectors of Xanthomonas oryzae neutralize R-gene-mediated plant disease resistance (2016) Ji et al. Nature Communications 7, Article number: 13435 (2016)

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 21 Jun 2017 14:12:48 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/255274460Mon, 13 Nov 2017 10:26:20 GMTSummary:

]]>Stage2.png

]]>Description:

]]>Advantage:

]]>References:Interfering TAL effectors of Xanthomonas oryzae neutralize R-gene-mediated plant disease resistance (2016) Ji et al. Nature Communications 7, Article number: 13435 (2016)

]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseSplicing Correction in Spinal Muscular Atrophy by Targeting Intronic Sequenceshttp://isurftech.technologypublisher.com/technology/25525Summary:
This technology has the potential to increase the Spinal Muscular Atrophy protein levels in patients with Spinal Muscular Atrophy. The innovation is a blocking antisense oligonucleotide and its target site located in a deep intronic sequence of the SMN2 gene. The blocking of the SMN2 target sequence corrects the defective splicing of the gene.

Stage1.png
Development Stage:

Description:
Humans possess two nearly identical copies of survival motor neuron (SMN) gene: SMN1 and SMN2. Loss of SMN1 coupled with the inability of SMN2 to compensate for loss of SMN1 causes spinal muscular atrophy (SMA), one of the leading genetic causes of infant mortality. SMN2 produces a truncated non-functional SMN protein (SMNΔ7) due to skipping of exon 7. It is generally believed that strategies aimed at correction of SMN2 exon 7 splicing hold great promise to cure SMA. By constructing and testing a series of overlapping deletions, Iowa State University researchers identified intronic positions 290 to 295 (LDI Site-1 or LS-1) as being involved in a long-distance inhibitory interaction. By carrying out an anti-sense micro walk the researchers observed that anti-sense oligonucleotides targeting LS-1 stimulate SMN2 exon 7 splicing in SMA patient cells. This is the first finding in which anti-sense oligonucleotide blocking of a deep intronic sequence has been found to correct the defective splicing of SMA gene.

Advantage:
• Low cost of synthesis due to small size
• High target specificity and low off-target effect
• Effective at very low dose
• Amenable to modifications for transport across blood brain barrier
• Unique mechanism of splicing regulation through modulation of catalytic core of spliceosome

Application:
Development of drugs for the treatment of spinal muscular atrophy

References:
1. Singh, N. N., Lawler, M. N., Ottesen, E. W., Upreti, D., Kaczynski, J. R., & Singh, R. N. (2013). An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy. Nucleic Acids Research, 41(17), 8144–8165.

2. Deep Intronic Target For Splicing Correction On Spinal Muscular Atrophy Gene, US patent application number 20150315582

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 21 Jun 2017 13:56:59 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/255254087Mon, 13 Nov 2017 10:26:18 GMTSummary:

]]>Stage1.pngDevelopment Stage:Description:

]]>Advantage:

]]>Application:

]]>References:Singh, N. N., Lawler, M. N., Ottesen, E. W., Upreti, D., Kaczynski, J. R., & Singh, R. N. (2013). An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy. Nucleic Acids Research, 41(17), 8144–8165.

2. Deep Intronic Target For Splicing Correction On Spinal Muscular Atrophy Gene, US patent application number 20150315582]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalseRapid Enrichment of Viable Bacteria using Magnetic Ionic Liquids for PCR Amplification and Culture-Based Diagnosticshttp://isurftech.technologypublisher.com/technology/25426Summary:
ISU researchers have developed new molecules with an accompanying method to preconcentrate bacteria for rapid detection for food safety testing.

Stage2.png
Development Stage:

Description:
The detection of viable bacteria in food, environmental, or clinical samples is limited by time-consuming enrichment procedures (e.g., overnight cultures) that are often mandatory for the analysis of extremely small quantities of microorganisms. Iowa State University researchers have developed new molecules to act as magnetic ionic liquids (MILs) and an method of use thereof to isolate, extract, and concentrate bacteria in an efficient manner for rapid testing purposes. These tunable MILs present unique physiochemical properties, resulting in materials that are responsive to external magnetic fields. Using this magnetism allows for easy separation of the MILs and extracted material from non-magnetic media. ISU inventors have demonstrated the ability of their specially designed MILs to be able to extract bacteria with high specificity. After a simple separation and culturing in broth, quantifiable colonization of recovered bacteria begins within two hours. This enrichment approach can be coupled with PCR amplification to further increase sample throughput. Regardless of downstream detection methods, MIL-based preconcentration of bacteria constitutes an enrichment strategy that allows for significantly faster detection of relevant bacteria for the food safety testing industry.

Advantage:
• Fast preconcentration of bacteria
• Allows for higher throughput of detection

Application:
Food safety testing, research tool

Patent:
Patent(s) applied for

Desc0000.png

]]>Fri, 02 Jun 2017 10:04:16 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/254264591Mon, 13 Nov 2017 10:26:14 GMTSummary:

]]>Stage2.pngDevelopment Stage:Description:

]]>Advantage:

]]>Application:Food safety testing, research toolPatent:Patent(s) applied forDesc0000.pngMarkJuettenAssociate Commercialization Manager, Chemistrymjuetten@iastate.eduFalseNovel exosome-based oligomeric alpha-synuclein protien biomarker discovery using the RT-QuIC assay platformhttp://isurftech.technologypublisher.com/technology/25425Summary:
ISU researchers have developed an assay for following the progression of parkinsonain disorders.

Stage3.png
Development Stage:

Description:
Parkinson's disease (PD) is a major neurodegenerative disorder affecting around 2% of the elder population in U.S, and its incidence is expected to rise dramatically with the advancing median age of the population. There are no current diagnostic tests or biomarker(s) to follow its progression. Current diagnosis and followup are mainly based on a thorough clinical history and neurological evaluation. ISURF #04583 is a method of use for RT-QuIC assay with remarkable accuracy targeting specifically Parkinson's disease (PD) and other parkinsonian disorders. Iowa State University researchers have demonstrated this technique to be rapid, sensitive, specific, and quantitative. The method is flexible, able to adopt to a variety of easily accessible samples including, but not limited to, body fluids like blood and urine. Thus far the researchers have demonstrated capability of detecting Mn poising (strongly linked to PD) in welders, a common occupational hazard.

Advantage:
• Fast
• Effective
• Selective

Application:
Identification and quantified tracking of Parkinson's disease and the family of Parkinsonian disorders.

Patent:
Patent(s) applied for

Desc0000.png

]]>Fri, 02 Jun 2017 10:04:15 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/254254583Mon, 13 Nov 2017 10:26:13 GMTSummary:

]]>Stage3.pngDevelopment Stage:Description:

]]>Advantage:

]]>Application:Identification and quantified tracking of Parkinson's disease and the family of Parkinsonian disorders.Patent:Patent(s) applied forDesc0000.pngMarkJuettenAssociate Commercialization Manager, Chemistrymjuetten@iastate.eduHealthcare| Life Sciences| Medical DevicesFalseTransparent soil made by gel beadshttp://isurftech.technologypublisher.com/technology/25370Summary:
This innovation appears to be the first description of using beads made with “natural” gelling materials to observe plant roots. The bead formulation is novel and optimized for plant growth.

Stage1.png
Development Stage:

Description:
ISU researchers reported their invention to be a transparent soil medium which can provide a heterogeneous environment with aeration and porous condition for plants. The medium is composed of commonly used gels and is transparent in a basal medium solution. The transparent soil composition is controllable, affordable, and require simple processing protocols. Brassica rapa grown in transparent soil shows root phenotypes resembling those of pure soils, as opposed to the phenotypes observed with homogeneous gels.

Advantage:
• Shelf life
• Aeration by using beads
• Potential for near infrared root imaging (no need for visible light)
• Easy to prepare

Desc0000.png

]]>Wed, 24 May 2017 13:57:50 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/253704601Mon, 13 Nov 2017 10:26:05 GMTSummary:

]]>Stage1.pngDevelopment Stage:Description:

]]>Advantage:]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseNovel anthelmintic drugshttp://isurftech.technologypublisher.com/technology/25369Summary:
This invention includes two new anthelmintic compounds. The compounds are (S)-5-ethynyl-anabasine and (S)-5-bromoanabasine. These compounds are both derivatives of the nicotine molecule and are agonists of a nicotinic ACh receptor. This invention may take advantage of the large market for animal parasiticides and the lack of existing patented drugs for deworming.

Stage2.png
Development Stage:
The current status of the invention is at the proof of concept stage.

Description:
Nematode parasites infect ~2 billion people world-wide and infections are treated and prevented by anthelmintic drugs, some of which act on nicotinic Acetyl Choline receptors (nAChRs). There is an unmet need for novel therapeutic agents because of concerns about the development of resistance. ISU researchers selected the Asu-ACR-16 receptor from a significant nematode parasite, Ascaris, as a pharmaceutical target and nicotine as the basic moiety to facilitate the development of a novel class of anthelmintics. Asu-ACR-16 was expressed in Xenopus oocytes and two-electrode voltage clamp electrophysiology and determined agonist concentration-current-response plots to estimate the potencies (EC50s) of the agonists. The researchers synthesized a novel agonist, (S)-5-ethynyl-anabasine, and show that it is more potent than other nicotine alkaloids on Asu-ACR-16. Other related (S)-5-ethynyl-anabasine derivatives have also been developed. Such agonists have the potential to circumvent drug resistance that has arisen following repeated treatment of nematode parasites with other classes of anthelmintic drugs and are a useful lead for anthelmintic drug development.

Advantage:
• Target nicotinic ACh receptor
• Based on easily derived chemical
• Can replace drugs to which resistance has been developed
• Potentially useful in both human and animal populations

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 24 May 2017 13:57:49 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/253694541Mon, 13 Nov 2017 10:26:04 GMTSummary:

]]>Stage2.pngDevelopment Stage:The current status of the invention is at the proof of concept stage.Description:

]]>Advantage:

]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life Sciences| Veterinary MedicineFalseImproved Spinach Aptamer Ligandshttp://isurftech.technologypublisher.com/technology/25064Summary:
Improved spinach (and broccoli) aptamer ligands for in vitro applications delivering increased signal intensity when associated with the target aptamer.

Stage3.png
Development Stage:

Description:
Light-up aptamers,which create a fluorescent signal on binding to their ligands, are promising sensors for in vitro homogeneous assays and for in vivo applications. When linked to other aptamers of defined specificity that drive their ability to bind ligand, these light-up aptamers can report on the presence of analytes in vitro that range from metabolites to proteins.
The Spinach aptamer creates a fluorescent signal on binding its 3,5-difluoro-4-hydroxybenzylidene imidazolinone ligand (DFHBI). DFHBI is widely used, despite having limitations such as low affinity and short fluorescent lifetime. This innovation introduces a new higher affinity ligands for Spinach aptamers including PFP-DFHBI, GSK132, and 11 additional derivatives. For example, PFP-DFHBI binds with a 40-fold higher affinity under intracellular conditions and a 3-fold increase in fluorescence yield as compared with DFHBI. Additional research favors the GK132 derivative as the optimal ligand.

Advantage:
• Increased signal strength
• Suitability for in vitro application
• Facile chemical synthesis protocols

References:
Ilgu, M., et al., Light-up and fret aptamer reporters; evaluating their applications for imaging transcription in eukaryotic cells. Methods, 2015. 98: p. 26-33

Patent:
Patent(s) applied for

Desc0000.png

]]>Wed, 12 Apr 2017 15:07:25 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/250644502Mon, 13 Nov 2017 10:25:52 GMTSummary:

]]>Stage3.pngDevelopment Stage:Description:The Spinach aptamer creates a fluorescent signal on binding its 3,5-difluoro-4-hydroxybenzylidene imidazolinone ligand (DFHBI). DFHBI is widely used, despite having limitations such as low affinity and short fluorescent lifetime. This innovation introduces a new higher affinity ligands for Spinach aptamers including PFP-DFHBI, GSK132, and 11 additional derivatives. For example, PFP-DFHBI binds with a 40-fold higher affinity under intracellular conditions and a 3-fold increase in fluorescence yield as compared with DFHBI. Additional research favors the GK132 derivative as the optimal ligand.

]]>Advantage:

]]>References:Ilgu, M., et al., Light-up and fret aptamer reporters; evaluating their applications for imaging transcription in eukaryotic cells. Methods, 2015. 98: p. 26-33

]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseNeurotransmitter transport in probioticshttp://isurftech.technologypublisher.com/technology/24015Summary:
The discovery of the existence of a neurotransmitter transport mechanism in some probiotics is disclosed as well as a method to identify suitable probiotic strains with high potential to modulate neurotransmitter levels in an animal or human host.

Stage2.png
Development Stage:

Description:
Probiotics are designated as living microorganisms that may be used for both maintenance of health as well as treatment of specific clinical conditions ranging from gastrointestinal infections to the treatment of neuropsychiatric-related behavioral issues. Probiotics are also extensively used in the farm production industry (chickens, pigs and cattle) as well as in the treatment of companion animals (dogs, cats, horses).

The inventor (Dr. Lyte) first proposed the creation of the field of microbial endocrinology in 1992 and recent research reports dramatic effects of microbes from the gut on mental function. Dr. Lyte reports in this disclosure that certain probiotic strains possess a neurotransmitter transporter system that would provide a mechanism by which to select probiotics for defined conditions, i.e., tailor the probiotic strain to the treatment. The identification of a neurotransmitter transporter system is reported to be novel. In addition, this disclosure identified an assay that can be used as the first step of a screening process to select potentially beneficial probiotic strains.

Advantage:
• Ability to identify probiotic strains influencing neurotransmitter levels.
• Simple screening method.

Application:
Discovery of beneficial probiotics capable to transport neurotransmitters

Group:
This technology is related to ISURF 4644: Probiotic treatment of gut inflammation

Patents:

Patent(s) Applied For

Desc0000.png

]]>Thu, 09 Feb 2017 14:10:49 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/240154568Mon, 13 Nov 2017 10:25:44 GMTSummary:

]]>Stage2.pngDevelopment Stage:Description:

The inventor (Dr. Lyte) first proposed the creation of the field of microbial endocrinology in 1992 and recent research reports dramatic effects of microbes from the gut on mental function. Dr. Lyte reports in this disclosure that certain probiotic strains possess a neurotransmitter transporter system that would provide a mechanism by which to select probiotics for defined conditions, i.e., tailor the probiotic strain to the treatment. The identification of a neurotransmitter transporter system is reported to be novel. In addition, this disclosure identified an assay that can be used as the first step of a screening process to select potentially beneficial probiotic strains.

]]>Advantage:

]]>Application:

]]>Group:ISURF 4644: Probiotic treatment of gut inflammation

]]>Patents:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life Sciences| Veterinary MedicineFalseSaracatinib (AZD0503) is a epilepsy treatment drug candidatehttp://isurftech.technologypublisher.com/technology/24014Summary:
Previous studies of the AZD0503/Saracatinib drug, a well-known fyn kinase inhibitor, have demonstrated excellent tolerability and bioavailability in humans. ISU researchers have discovered that the drug reduces seizure onset in the mouse kainate model of temporal lobe epilepsy. Thus, the drug has potential for the treatment of epilepsy in humans.

Stage1.png
Development Stage:

Description:
Chemoconvulsant-induced status epilepticus in rodents can lead to the development of temporal lobe epilepsy (TLE).  ISU researchers unexpectedly found that the fyn kinase, a non-receptor tyrosine kinase, is up-regulated in microglial cells in a mouse kainate (KA) model of TLE. The researchers hypothesized that reducing the levels of fyn kinase would prevent seizure onset, decrease the severity of SE, and the brain pathology associated with epileptogenesis.

The fyn kinase hypothesis was tested in the fyn knockout mice (fyn -/-) with appropriate fyn+ /+ controls with saracatinib (25 mg/kg, oral, single dose) 4h prior to the induction of SE with KA (5mg/kg, i.p. at 30 min intervals or as a single high dose of 25 mg/kg). Two hours after SE establishment,  the behavioral SE was terminated, the animals euthanized, and the brain, serum, and cerebrospinal fluid were collected for various analyses. Brain tissues were processed for Immunohistochemistry and western blot  analysis. The time-dependent activation of fyn in microglial cells and initiation of neuro-inflammatory and neurodegenerative mechanisms in the hippocampus at 4h, 24h and 7day time points post-SE were also examined, and a electroencephalographic (EEG) analysis to determine the spike rate and SRS frequency was performed. 

The behavioral studies revealed a significant reduction in the severity of the seizures and the time spent in convulsive motor seizures (CMS) stages in the fyn-/- mice and saracatinib treated mice during the 2h established SE. The mortality rate in the fyn-/- mice was lower than the fyn+/+ mice. The number of spontaneous electrographic non-convulsive seizures, the duration of CMS, and the spike frequency were also reduced in the fyn-/- mice. The epileptiform spike rate was higher in fyn+/+ mice during the first 7 days, but they decreased thereafter. IHC analysis of brain sections revealed a significant increase in fyn, PKC-δ, oxidative and nitrative stress markers (GP-91phox, 4-HNE, 3NT)  in the microglia in the dentate gyrus, CA3 and CA1 at 4h and 24h post-SE in fyn+/+ mice. These levels were significantly reduced in the fyn-/- mice. Also, a significant increase in the fyn and PKC-δ nuclear translocation in reactive microglia at 24h post SE was detected in the fyn+/+ mice  vs. the fyn-/- mice, suggesting their role in the pro-inflammatory responses. Quantitative RT-PCR analysis revealed an increase in the TNF-α, IL-1β and iNOS mRNA levels in controls when compared with the fyn-/-mice. In the 24h group, hippocampal western blots revealed down-regulation of fyn, PKC-δ, phospho Src-416, phospho PKCδ-507, GP-91phox, 4-HNE and caspase-3 levels in fyn-/-mice vs. fyn+/+mice. Moreover, an increase in the numbers of FJB-positive neurons was observed in the CA3 and CA1 regions of the hippocampus at 24h post-SE in fyn+/+ mice vs. fyn-/- mice.

Advantage:
• Repurposed experimental cancer drug
• Drug has excellent tolerability and bioavailability in humans
• Potential to treat epilepsy with fyn kinase inhibitors
• Ongoing clinical trials for non-epilepsy indications

Application:
Treatment of epilepsy using Saracatinib or another fyn kinase inhibitor.

References:
Fyn kinase increases seizure susceptibility by regulating neuro-inflammatory response in reactive microglia in the hippocampus in a mouse kainate model of temporal lobe epilepsy

Patent:
Patent(s) applied for

Desc0000.png

]]>Thu, 09 Feb 2017 13:51:16 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/240144550Mon, 13 Nov 2017 10:25:42 GMTSummary:

]]>Stage1.pngDevelopment Stage:Description:

The fyn kinase hypothesis was tested in the fyn knockout mice (fyn -/-) with appropriate fyn+ /+ controls with saracatinib (25 mg/kg, oral, single dose) 4h prior to the induction of SE with KA (5mg/kg, i.p. at 30 min intervals or as a single high dose of 25 mg/kg). Two hours after SE establishment,  the behavioral SE was terminated, the animals euthanized, and the brain, serum, and cerebrospinal fluid were collected for various analyses. Brain tissues were processed for Immunohistochemistry and western blot  analysis. The time-dependent activation of fyn in microglial cells and initiation of neuro-inflammatory and neurodegenerative mechanisms in the hippocampus at 4h, 24h and 7day time points post-SE were also examined, and a electroencephalographic (EEG) analysis to determine the spike rate and SRS frequency was performed. 

The behavioral studies revealed a significant reduction in the severity of the seizures and the time spent in convulsive motor seizures (CMS) stages in the fyn-/- mice and saracatinib treated mice during the 2h established SE. The mortality rate in the fyn-/- mice was lower than the fyn+/+ mice. The number of spontaneous electrographic non-convulsive seizures, the duration of CMS, and the spike frequency were also reduced in the fyn-/- mice. The epileptiform spike rate was higher in fyn+/+ mice during the first 7 days, but they decreased thereafter. IHC analysis of brain sections revealed a significant increase in fyn, PKC-δ, oxidative and nitrative stress markers (GP-91phox, 4-HNE, 3NT)  in the microglia in the dentate gyrus, CA3 and CA1 at 4h and 24h post-SE in fyn+/+ mice. These levels were significantly reduced in the fyn-/- mice. Also, a significant increase in the fyn and PKC-δ nuclear translocation in reactive microglia at 24h post SE was detected in the fyn+/+ mice  vs. the fyn-/- mice, suggesting their role in the pro-inflammatory responses. Quantitative RT-PCR analysis revealed an increase in the TNF-α, IL-1β and iNOS mRNA levels in controls when compared with the fyn-/-mice. In the 24h group, hippocampal western blots revealed down-regulation of fyn, PKC-δ, phospho Src-416, phospho PKCδ-507, GP-91phox, 4-HNE and caspase-3 levels in fyn-/-mice vs. fyn+/+mice. Moreover, an increase in the numbers of FJB-positive neurons was observed in the CA3 and CA1 regions of the hippocampus at 24h post-SE in fyn+/+ mice vs. fyn-/- mice.

]]>Advantage:

]]>Application:

]]>References:Fyn kinase increases seizure susceptibility by regulating neuro-inflammatory response in reactive microglia in the hippocampus in a mouse kainate model of temporal lobe epilepsy

]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalseCampylobacter jejuni peptide for vaccine developmenthttp://isurftech.technologypublisher.com/technology/23910Summary:
A promising target for designing a diagnostic test and peptide sequence for vaccine development to control Campylobacter jejuni infections in ruminants and humans.

Stage1.png
Development Stage:

Description:
Campylobacter jejuni is a major causative agent for abortion in ruminants, particularly in sheep. It is also a major foodborne pathogen and a leading cause of enteritis in humans, responsible for 400-500 million cases of diarrhea annually worldwide each year. In the U.S. alone, C. jejuni accounts for more than 800,000 cases of foodborne illnesses each year. A hyper virulent clone of C. jejuni is the predominant cause of sheep abortion in the U.S. This disclosure identifies a peptide (AEEQGADLLGKSTISTTQKAAPFQADSLGNL) in the predicted external loop 4 of the major outer membrane protein of C. jejuni, which is essential for its hyper-virulence in inducing abortion. The loop 4 sequence is critical for virulence and provides a promising target for designing a diagnostic test and for vaccine development to control C. jejuni infections.

Advantage:
• Subunit vaccine
• Highly specific target
• No need to culture the pathogen

References:
1. September 6, 2016. Journal Article. Point mutations in the major outer membrane protein drive hypervirulence of a rapidly expanding clone of Campylobacter jejuni /PNAS USA

2. Sahin et al. Emergence of a tetracycline resistant campylobacter jejuni clone associated with outbreaks of ovine abortion in the United States. J. Clin. Microbiol. May 2008 p. 1663-1671

Patent:
Patent(s) applied for

Desc0000.png

]]>Tue, 31 Jan 2017 13:58:24 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/239104559Mon, 13 Nov 2017 10:25:41 GMTSummary:

]]>Stage1.pngDevelopment Stage:Description:

]]>Advantage:

]]>References:1. September 6, 2016. Journal Article. Point mutations in the major outer membrane protein drive hypervirulence of a rapidly expanding clone of Campylobacter jejuni /PNAS USA

2. Sahin et al. Emergence of a tetracycline resistant campylobacter jejuni clone associated with outbreaks of ovine abortion in the United States. J. Clin. Microbiol. May 2008 p. 1663-1671 ]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineFalseInduction Protocol for Bovine Digital Dermatitis Lesions Using a Cocktail of Pure Growth Organismshttp://isurftech.technologypublisher.com/technology/23907Summary:
ISURF #4258 describes a method for inducing papillomatous digital dermatitis (PDD) in cattle, an important disease for the US dairy industry that is leading cause of lameness.  Also disclosed are a number of bacterial isolates that are used to induce the disease model for this polymicrobial infection.  Advantages of this technology include lower cost, more faithful and consistent replication of lesions seen with the natural disease, and rapid disease induction.

Stage2.png
Development Stage:

Description:
Digital dermatitis (DD) is an economically important polymicrobial disease process of dairy cattle that, despite 35 years of research, remains etiologically undefined. It is the leading cause of lameness in US dairy cattle. In addition to the cost associated with treatment and lost production, it represents a significant welfare concern for the industiy. For these reasons, lameness, and specifically DD, was ranked as the top priority by Daily Industry Stakeholders at the 2010 USDA ARS-NIFA Anitnal Health Research Planning Workshop. Although the disease  is responsive to antibiotics, a definitive bacterial cause has not been identified. Treponema spp. are regularly isolated from DD lesions, however attempts to induce classic disease lesions with pure culture of these microorganisms remain universally unsuccessful. Based on these findings, and the lack of efficacy of Treponema based vaccines, it is widely believed that the disease is polybacterial in nature. The identity of microorganisms that work in concert with Treponema spp. to cause the clinical presentation of DD in cattle has remained unknown. Lack of this knowledge is an inportant problem because it prevents the development of effective intervention strategies that target the causative agents of DD. One important tool for studying this disease process is the development of a consistent model of disease induction that results in lesions characteristic of the naturally occurring lesions. Such a model will allow for indepth study of the disease pathogenesis, experimental studies to try and fulfill identification of causative organisms and most importantly a model useful for testing experimental interventions (vaccines, treatments, prevention etc). This disclosure describes a novel induction method useful for inducing digital dermatitis lesions that appear consistent with the natural disease process. Furthermore, this method results in reasonably quick induction in the characteristic site of lesion development. Previous induction methods that have been attempted either do not provide consistent results or induce lesions that are not consistent with natural disease.

Advantage:
• Lesions consistent with the natural disease process
• Availability of isolates
• Potential for marked improvement vs. current approaches

Application:
Veterinary Research

References:
Animal Model Protocol, Diagnostic, Therapeutic And Vaccine Against Digital Dermatitis, US 2016/0256575


 

Patent:
Patent(s) applied for

Desc0000.png

]]>Tue, 31 Jan 2017 13:17:47 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/239074258Mon, 13 Nov 2017 10:25:40 GMTSummary:

]]>Stage2.pngDevelopment Stage:Description:

]]>Advantage:

]]>Application:

]]>References:Animal Model Protocol, Diagnostic, Therapeutic And Vaccine Against Digital Dermatitis, US 2016/0256575

]]>Patent:Patent(s) applied forDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineFalseInsect toxin delivery mediated by a densovirus coat proteinhttp://isurftech.technologypublisher.com/technology/23906Summary:
A Junonia coenia densovirus coat protein with potential to create fusion proteins expressed in transgenic crops to control the fall armyworm.

Stage1.png
Development Stage:

Description:
The fall armyworm is a continuous resident of the Gulf States. Corn, sorghum, and other plants of the grass family are its preferred foods, but the fall armyworm also attacks alfalfa, bean, peanut, potato, sweet potato, turnip, spinach, tomato, cabbage, cucumber, cotton, tobacco, all grain crops, and clover. Each year the fall armyworm can be found as far north as Montana, Michigan, and New Hampshire. In the southeast it occurs annually on late corn.

In this disclosure, ISU researchers report a discovery that may be exploited to develop a technology to control the armyworm without using chemical insecticides. The finding is that the VP4 coat protein from the Junonia coenia Densovirus rapidly crosses the midgut epithelium of this insect. Thus, there is an opportunity to develop effective insecticidal VP4/toxin fusion proteins capable to kill the worm by ingestion of the toxic proteins produced endogenously in a biotech crop.

Advantage:
• Possible alternative to chemical insecticides
• Likely not to disrupt non-plant eating insects
• Potential for high specificity
Application:
Pest control in plant agriculture.

References:
Delivery of intrahemocoelic peptides for insect pest management. (Review)
Bryony C. Bonning and Nanasaheb P. Chougule
Trends in Biotechnology Vol 32 (2) 91-98 (2014)

Patent:
Patent(s) applied for

Desc0000.png

]]>Tue, 31 Jan 2017 13:10:19 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/239064563Mon, 13 Nov 2017 10:25:39 GMTSummary:

]]>Stage1.pngDevelopment Stage:Description:

In this disclosure, ISU researchers report a discovery that may be exploited to develop a technology to control the armyworm without using chemical insecticides. The finding is that the VP4 coat protein from the Junonia coenia Densovirus rapidly crosses the midgut epithelium of this insect. Thus, there is an opportunity to develop effective insecticidal VP4/toxin fusion proteins capable to kill the worm by ingestion of the toxic proteins produced endogenously in a biotech crop.]]>Advantage:Application:

]]>References:Delivery of intrahemocoelic peptides for insect pest management. (Review)
Bryony C. Bonning and Nanasaheb P. Chougule
Trends in Biotechnology Vol 32 (2) 91-98 (2014)

]]>Patent:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseIdentification of Bt toxins to target Asian Citrus Psyllid for HLB treatment in citrushttp://isurftech.technologypublisher.com/technology/22825Summary:
ISU researchers have identified several Cry toxins from the bacterium Bacillus thuringiensis (Bt) for the management of Asian Citrus Psyllid (ACP) and the associated HLB disease in the citrus industry.

Description:
The Asian citrus psyllid (ACP, Diaphorina citri Kuwayama) is an important pest of citrus in several countries. ACP can transmit bacterium, Candidatus Liberibacter asiaticus, which causes a devastating citrus disease called huanglongbing (HLB), also known as citrus greening disease. The disease destroys citrus trees in many countries and states, including Florida. It is estimated that this insect-disease combination has cost the citrus industry in Florida $1.3 billion in losses. Currently, ACP management is mainly driven by chemical insecticide applications, but these are costly and insecticide resistance in ACP has been noted. It also has non-target impacts on beneficial insects including butterflies and honeybees. To address this problem, insecticidal toxins derived from the bacterium Bacillus thuringiensis (Bt) is adopted as an environmentally benign alternative to the application of chemical insecticides. ISU researchers screened multiple strains of Bt for toxicity against ACP and identified that 1) combinations of toxins derived from six strains of Bt are toxic to ACP. 2) Two individual toxins Cry1Ab and Cry1B derived from one of these strains are toxic to ACP. 3) Cry1Ab can be modified with four ACP gut-binding peptides to enhance toxicity against ACP. This method would provide a more sustainable and environmentally friendly approach for management of ACP and the associated HLB disease than repeated application of broad-spectrum insecticides.

Advantage:
• An economic and efficient way for the management of ACP
• Ecofriendly and beneficial to the public health
• Have no detrimental impact on beneficial insects (e.g. honeybee)

Application:
Insect control

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Fri, 09 Sep 2016 12:13:14 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/228254477Mon, 13 Nov 2017 10:25:03 GMTSummary:

]]>Description:

]]>Advantage:Application:]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseMitoapocynin: A potential antiepileptogenic agenthttp://isurftech.technologypublisher.com/technology/22824Summary:
ISU researchers have synthesized an orally available derivative of apocynin, Mitoapocynin (Mito-Apo) for the treatment of seizures.

Description:
A seizure is a sudden alteration in normal brain activity that results in distinct changes in behavior or body function, which can be caused by stroke, brain tumors, metabolic disturbances, and others. It has been reported that mitochondrial dysfunction associated with oxidative stress and neuroinflammation could contribute to the occurrence of seizures. However, currently there is a lack of a pharmacological agent that can intervene in all key pathological mechanisms. To overcome this problem, Researchers at ISU have synthesized an orally available derivative of apocynin, Mitoapocynin (Mito-Apo), which was previously tested to target mitochondria and protect against oxidative damage, glial-mediated inflammation and nigrostrital neurodegeneration in the animal model of PD. In the current animal model, Mito-apo showed excellent central nervous system (CNS) bioavailability even at a very low dose (3mg/kg, oral). At I0 mg/kg (oral, as a single dose), it attenuated the severity and duration of convulsive seizures, and increased the latency to the onset of convulsive seizures as well as protected against seizure induced mortality.

Advantage:
• Easy to be synthesized in the laboratory
• Available in oral dosage form
• Enhanced cellular and mitochondrial uptake, and effective at a low dosage

Application:
seizures drug discovery

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Fri, 09 Sep 2016 12:13:13 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/228244467Mon, 13 Nov 2017 10:25:03 GMTSummary:

]]>Description:A seizure is a sudden alteration in normal brain activity that results in distinct changes in behavior or body function, which can be caused by stroke, brain tumors, metabolic disturbances, and others. It has been reported that mitochondrial dysfunction associated with oxidative stress and neuroinflammation could contribute to the occurrence of seizures. However, currently there is a lack of a pharmacological agent that can intervene in all key pathological mechanisms. To overcome this problem, Researchers at ISU have synthesized an orally available derivative of apocynin, Mitoapocynin (Mito-Apo), which was previously tested to target mitochondria and protect against oxidative damage, glial-mediated inflammation and nigrostrital neurodegeneration in the animal model of PD. In the current animal model, Mito-apo showed excellent central nervous system (CNS) bioavailability even at a very low dose (3mg/kg, oral). At I0 mg/kg (oral, as a single dose), it attenuated the severity and duration of convulsive seizures, and increased the latency to the onset of convulsive seizures as well as protected against seizure induced mortality.Advantage:Application:]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalseHigh-number Gene Fragment Assemblyhttp://isurftech.technologypublisher.com/technology/22741Summary:
ISU researchers have developed a method that can assembly up to 45 fragments into a full-length gene sequence with only two steps, the assembly step and the PCR step.

Description:
Gene synthesis technology, in contrast to gene engineering, is a method in synthetic biology that is used to create genes de novo. It has become a powerful tool in many fields of recombinant technology including gene therapy, vaccine development and molecular engineering. Current approaches are mostly based on a combination of organic chemistry and molecular biological technique, and requires multiple steps to successfully assembly a full-length gene. For instance, oligonucleotide ligation and PCR-based assembly. Also, the number of DNA fragments in one assembly is always limited to 11 or even less. To solve this problem, ISU researchers have developed an assembly method with the help of the thermodynamic analysis software PICKY created by the same group previously. The assembly method can push the limit up to 45 fragments and only needs two steps in one reaction tube, the assembly step and the PCR step. With this technique, companies can synthesize much longer genes with many fragments using one reaction instead of the tiered assembly scheme. This will improve both the cost and quality of gene synthesis services.

Advantage:
• Allows high number fragments (up to 45) in one assembly reaction
• Able to synthesize longer genes for various follow-up experiments
• Low-cost and high quality gene synthesis service
• Easy to be adapted in the laboratory

Application:
Gene synthesis

Patent:
Copyrighted Material - Software

Group:
This technology is related to ISURF 3554: PICKY: An Optimal Oligonucleotide Design and Analysis Tool

Stage2.png
Development Stage:

Desc0000.png

]]>Thu, 25 Aug 2016 15:08:56 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/227414280Mon, 13 Nov 2017 10:25:00 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>Patent:Copyrighted Material - SoftwareGroup:ISURF 3554: PICKY: An Optimal Oligonucleotide Design and Analysis Tool

]]>Stage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseSaracatinib, an anti-inflammatory effect of orally active Fyn kinase inhibitor against Parkinson's diseasehttp://isurftech.technologypublisher.com/technology/22740Summary:
ISU researchers have discovered a pharmacological inhibitor of Fyn kinase, Saracatinib, to block the microglial activation and neuroinflammation in Parkinson’s disease.

Description:
Parkinson’s disease (PD), a chronic and progressive movement disorder, remains the second most common neurodegenerative disease with a substantial socioeconomic burden in ageing populations. Primary motor signs of PD include tremors, slowness of movement, rigidity and postural instability. Current treatments primarily tend to control symptoms of PD with no effective ways to slow or halt disease progression. To address this problem, researchers at ISU recently identified that Fyn-PKCδ signaling pathway drives microglial activation and neuroinflammation to promote disease progression in cell culture and animal models of PD. It is the first report ever to demonstrate that Fyn tyrosine kinase is a key drug target for PD and other related neurodegenerative diseases. Based on this discovery, a tyrosine kinase inhibitor, Saracatinib (AZD-0530) was found to effectively block Fyn-PKCδ signaling pathway to suppress microglial activation and neuroinflammatory cascade in PD models.

Advantage:
• First discovery found to block PD disease progression by targeting Fyn kinase
• Anti-inflammatory effect in PD cell culture and animal models

Application:
Pharmaceutical development for Parkinson’s disease

References:
Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease. Panicker, N., et al., 2015. J. Neurosci. 35, 10058-10077

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Thu, 25 Aug 2016 14:48:20 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/227404431Mon, 13 Nov 2017 10:24:59 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease. Panicker, N., et al., 2015. J. Neurosci. 35, 10058-10077]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalseSpinal Muscular Atrophy: A streamlined reporter system to screen for therapeutic compoundshttp://isurftech.technologypublisher.com/technology/22400Summary:
ISU researchers have developed a reporter system based on an abbreviated version of the SMN2 gene to screen potential therapeutic compounds involved in the transcription, splicing and translation of SMN2.

Description:
Pre-mRNA splicing is a complex molecular process involving RNA transcription, 5' and 3'-end RNA processing, and multiple RNA processing proteins. Humans have two nearly identical copies of the Survival Motor Neuron (SMN) gene: SMN1 and SMN2. Skipping of SMN2 exon 7 during pre-mRNA splicing results in a truncated SMN2 transcript which is quickly destroyed inside the cells. In individuals missing a functional SMN1 gene, exon 7 skipping in the SMN2 gene leads to Spinal muscular atrophy (SMA), a devastating neurodegenerative disorder. Strategies aimed at preventing SMN2 exon 7 skipping have shown promise for the therapy of SMA.
Currently, there is a need for a streamlined reporter system for the facile screening of therapeutic compounds that regulate transcription, splicing, and translation of SMN2. To address this need, ISU researchers constructed a reporter system which is essentially a small version of SMN2 (“Super SMN2 Minigene”). Specifically, the Super SMN2 Minigene system incorporates the SMN2 promoter, a FLAG tag for easy detection, all exons, flanking intronic sequences, and a 3’-untranslated terminal region. The Super SMN2 Minigene system is ideally suited for screening a broad range of compounds that are involved in regulating the transcription, splicing, 3'-end processing, transport and translation of SMN2, and it appears to be the most advanced system available.

Advantage:
• Easy laboratory implementation and less costly
• Ideal for identifying potential drugs for SMA therapy
• Likely to be the most advanced reporter available in the market today.

Application:
SMA Drug Discovery

Intellectual Property:
Tangible Material

Stage2.png
Development Stage:

Desc0000.png

]]>Wed, 06 Jul 2016 10:18:11 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/224004461Mon, 13 Nov 2017 10:24:40 GMTSummary:

]]>Description:Currently, there is a need for a streamlined reporter system for the facile screening of therapeutic compounds that regulate transcription, splicing, and translation of SMN2. To address this need, ISU researchers constructed a reporter system which is essentially a small version of SMN2 (“Super SMN2 Minigene”). Specifically, the Super SMN2 Minigene system incorporates the SMN2 promoter, a FLAG tag for easy detection, all exons, flanking intronic sequences, and a 3’-untranslated terminal region. The Super SMN2 Minigene system is ideally suited for screening a broad range of compounds that are involved in regulating the transcription, splicing, 3'-end processing, transport and translation of SMN2, and it appears to be the most advanced system available.

]]>Advantage:Application:

]]>Intellectual Property:

]]>Stage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalsePlant Protein and Biochar Fertilizerhttp://isurftech.technologypublisher.com/technology/21701Summary:
ISU researchers have developed a new, bio-char-based fertilizer that solves the problem of biochar application and incorporated additional biorenewable components for soil conditioning and enhanced nutrient availability.

Description:
Consumer demands for environmentally friendly products continue to rise. Public concern over pollution and other negative environmental impacts from chemical production have created a great interest in alternative chemical products produced from bio-based feedstocks and end-use chemical products that incorporate both bio-based chemicals and green chemistry principles.

The technology involves the use of soy flour and biochar materials to form a bio-derived fertilizer with soil conditioner. Recent studies have demonstrated that biochar can retain fertilizing chemicals, enhance plant growth, improve cation exchange capacity, and reduce greenhouse gas emissions when used as a soil additive. Previous research by the inventors has shown that soy-based plastics can be compounded with biochar to serve as an effective fertilizer and soil conditioner. The soy protein provides nutritional effects and stabilizes the biochar material. Biochar is a fine, black powder that cannot be spread onto soil without the addition of a binder or carrier. It is not possible to dispense the fine biochar powder directly because the wind would carry the powder uncontrollably. We have shown that it is possible to use pellets produced from soy plastic and bio-char to disperse this bio-based fertilizer easily and effectively.

Advantage:
• Environmentally Friendly
• Less Expensive Feedstocks
• Efficient Without Synthetic Fertilizers
• Competitive Production Costs

Application:
Lawn and Garden Fertilizer

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Thu, 07 Apr 2016 13:57:07 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/217014288Mon, 13 Nov 2017 10:24:01 GMTSummary:

]]>Description:

The technology involves the use of soy flour and biochar materials to form a bio-derived fertilizer with soil conditioner. Recent studies have demonstrated that biochar can retain fertilizing chemicals, enhance plant growth, improve cation exchange capacity, and reduce greenhouse gas emissions when used as a soil additive. Previous research by the inventors has shown that soy-based plastics can be compounded with biochar to serve as an effective fertilizer and soil conditioner. The soy protein provides nutritional effects and stabilizes the biochar material. Biochar is a fine, black powder that cannot be spread onto soil without the addition of a binder or carrier. It is not possible to dispense the fine biochar powder directly because the wind would carry the powder uncontrollably. We have shown that it is possible to use pellets produced from soy plastic and bio-char to disperse this bio-based fertilizer easily and effectively.

]]>Advantage:

]]>Application:

]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740False<![CDATA[Foxtail Mosaic Virus Transient Gene Silencing Vector for Maize & other Monocots]]>http://isurftech.technologypublisher.com/technology/21318Summary:
Plant viruses have been widely used as vectors for foreign gene expression and virus-induced gene silencing (VIGS). A limited number of viruses have been developed into viral vectors for the purpose of VIGS in monocotyledonous plants and only one has been shown to infect maize. ISU researchers have developed a new DNA-based VIGS system derived from Foxtail mosaic virus (FMV) which is able to establish systemic infection and silencing of endogenous maize genes homologous to gene fragments inserted into the FMV viral vector. Proof-of-concept VIGS applications of this vector system was accomplished by silencing two genes in the sweet corn line Golden Bantam. In addition, the research demonstrated that the FMV vector establishes systemic infection in maize inbred lines, sorghum, and green foxtail, indicating the potential wide applications of this viral vector system for functional genomic studies in maize and other monocots.

Advantage:
• Monocot-specific vector
• Proven to work in Maize, Sorghum, and Green Foxtail
• Transient expression enables high-throughput

Application:
Agricultural Research

Patent:
Patent(s) applied for

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 01 Feb 2016 12:20:34 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/213184344Mon, 13 Nov 2017 10:23:50 GMTSummary:

]]>Advantage:

]]>Application:

]]>Patent:Patent(s) applied forStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalsemiRNA396 as a Tool to Control Cyst Nematodeshttp://isurftech.technologypublisher.com/technology/21075Summary:
The innovation is a molecular target to develop plants with enhanced resistance to nematodes.

Description:
ISU researchers have demonstrated that the miRNA396-GRF regulatory unit in the model plant Arabidopsis mediates parasitism by the sugar beet nematode. Furthermore, the data indicates that the miRNA396 represents a key regulator for the reprogramming of root cells representing a powerful molecular target for the animal. Since miRNA396 is highly conserved in plants, manipulation of its expression in  agronomic crops may also lead to enhanced resistance to nematodes.

Advantage:
• Molecular modification approach
• Potential utility in many crop species

Application:
Construction of transgenic or gene edited plants with enhanced resistance to nematodes

References:
1. The Arabidopsis MicroRNA396-GRF1/GRF3 Regulatory Module Acts as a Developmental Regulator in the Reprogramming of Root Cells during Cyst Nematode Infection1,[W][OA] Tarek Hewezi, Tom R. Maier, Dan Nettleton, and Thomas J. Baum*

Patent:
Patent(s) applied for

Stage1.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 14:16:57 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210753900Mon, 13 Nov 2017 10:23:48 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>References:The Arabidopsis MicroRNA396-GRF1/GRF3 Regulatory Module Acts as a Developmental Regulator in the Reprogramming of Root Cells during Cyst Nematode Infection1,[W][OA] Tarek Hewezi, Tom R. Maier, Dan Nettleton, and Thomas J. Baum*

]]>Patent:Patent(s) applied forStage1.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalsePDCoV S1 Protein ELISA for Detection of Porcine Delta Coronavirushttp://isurftech.technologypublisher.com/technology/21074Summary:
Researchers at Iowa State University have developed an ELISA assay for the detection of Porcine Delta Coronavirus based on the use of a recombinant S1 viral protein.

Description:
Porcine Delta Coronavirus (PDCoV) was first diagnosed in North America in early 2014 where it was associated with enteric disease in pigs. While assays detecting nucleic acids of the virus were implemented quickly, assays to detect anti-PDCoV antibodies lagged far behind. Iowa State Researchers led the development of an indirect PDCoV anti-IgG enzyme-linked immunosorbent assay (ELISA) based on the putative S1 portion of the spike protein. The assay has been validated and was utilized to determine the prevalence of PDCoV in U.S. pigs. The diagnostic sensitivity of the PDCoV ELISA was 91% with a diagnostic specificity of 95%. ISURF is making the materials available under a non-exclusive license.

Advantage:
• S1 protein has been used to validate PDCoV detection
• Detects IgG antibodies
• S1 polypeptide antigen highly conserved for broad detection

Application:
Veterinary Diagnostics

References:
1. PLoS One. 2015; 10(4): e0124363. Published online 2015 Apr 16. doi:  10.1371/journal.pone.0124363  PMCID: PMC4399883

2. Development and Application of an ELISA for the Detection of Porcine Deltacoronavirus IgG Antibodies, Anil Thachil,1 Priscilla F. Gerber,2 Chao-Ting Xiao,1 Yao-Wei Huang,3 and Tanja Opriessnig1,2,*

Intellectual Property:
Tangible Material

Stage3.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 13:18:28 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210744296Mon, 13 Nov 2017 10:23:47 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>References:

2. Development and Application of an ELISA for the Detection of Porcine Deltacoronavirus IgG Antibodies, Anil Thachil,1 Priscilla F. Gerber,2 Chao-Ting Xiao,1 Yao-Wei Huang,3 and Tanja Opriessnig1,2,*

]]>Intellectual Property:Tangible MaterialStage3.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Life Sciences| Veterinary MedicineFalsePEDV S1 Protein ELISA for Detection of Porcine Epidemic Diarrhea Virushttp://isurftech.technologypublisher.com/technology/21073Summary:
Researchers at Iowa State University have developed an ELISA assay for the detection of Porcine Epidemic Diarrhea Virus (PEDV) based on the use of the PEDV S1 protein. The assay is capable of detecting anti-PEDV antibody of various classes (IgG, IgA or IgM) in serum, oral fluid, feces, and in colostrum and milk.

Description:
Laboratory diagnosis for PEDV is often performed using PCR as PEDV is difficult to culture; in addition, PEDV can resemble transmissible gastroenteritis (TGE) clinically, so it is important for herd management to understand the cause of acute diarrhea in infected pigs. Other methods used for diagnosis include clinical signs, history, ELISA, examination of feces for virus using electron microscopy, and post-mortem examination. This technology circumvents many of the difficulties and time constraints associated with these traditional methods. ISURF is making the materials available under a non-exclusive license.

Advantage:
• Works with a number of biological samples
• Detects various classes of Ig
• Can be used with a variety of sample types

Application:
Veterinary Diagnostics

Intellectual Property:
Tangible Material

Stage3.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 13:18:27 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210734295Mon, 13 Nov 2017 10:23:46 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Intellectual Property:Tangible MaterialStage3.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Life Sciences| Veterinary MedicineFalsePorcine Deltacoronavirushttp://isurftech.technologypublisher.com/technology/21072Summary:
ISU researchers have identified, purified, and characterized a cell-culture derived, plaque-cloned isolate of porcine deltacoronavirus (“ISU isolate”) from a clinical case

Description:
The ISU isolate has been adapted for propagation in a swine cell line for easy manipulation in vitro and its full-length genome has been sequenced. The ISU isolate has been demonstrated to cause diarrheic disease in conventional growing pigs, suggesting that it retains its original pathogenicity. The ISU isolate can be used as antigen for various vaccine formula (e.g., live, killed, genetically modified) and antibody production (both monoclonal and polyclonal antibodies) as well as for antibody assays (e.g., indirect FA test, ELISA, SN, Western immunoblot). Other uses include; positive control for viral assays such as PCR assays, and virus isolation.

Advantage:
• Adapted to growth in culture
• Can be used as antigen for various vaccine formula and antibody production
• Can be used as a positive control for viral assays such as PCR assays, and virus isolation

Application:
Veterinary Diagnostics

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 13:18:26 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210724425Mon, 13 Nov 2017 10:23:45 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Intellectual Property:Tangible MaterialStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Life Sciences| Veterinary MedicineFalseA Novel Facultative Methylotroph, Methylocystis daltona SB2http://isurftech.technologypublisher.com/technology/21066Description:
Methylocystis daltona SB2 (SB2) is a novel facultative methanotroph capable of utilizing methane and other multi-carbon substrates for growth has been identified.  SB2 constitutively expresses methane monooxygenase, enabling bioremediation of cholorinated solvents, enhanced removal of methane from the atmosphere, and for controlling emission of methane from multiple sources, including landfills and concentrated animal feeding operations.
SB2 also produces a novel chalkophore, or copper-binding compound, and may be used for removal of metals from aqueous systems, removal of mercury from gaseous waste streams, and the production of nanoparticles from precious metals (gold, rhodium, platinum and palladium).
This is the first example of a prokaryotic system capable of these functions.

Advantage:
• Versatile
• More effective than current bioremediation solutions

Application:
• Remediation of chlorinated solvents
• Remediation of methane from the atmosphere; controlling methane emission from landfills, animal production facilities, etc.
• Removal of metals from aqueous solutions
• Removal of mercury from gaseous waste streams
• Production of nanoparticles from precious metals

References:
N. Bandow et al. “Spectral and copper binding properties of methanobactin from the facultative methanotroph Methylocystis strain SB2”, Journal of Inorganic Biochemistry, 110, pp.72-82, 2012.  DOI: 10.1016/j.jinorgbio.2012.02.002. Epub 2012 Feb 12. PubMed PMID: 22504273.

Stage2.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 08:45:17 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210663802Mon, 13 Nov 2017 10:23:41 GMTDescription:SB2 also produces a novel chalkophore, or copper-binding compound, and may be used for removal of metals from aqueous systems, removal of mercury from gaseous waste streams, and the production of nanoparticles from precious metals (gold, rhodium, platinum and palladium).
This is the first example of a prokaryotic system capable of these functions.

]]>Advantage:

]]>Application:• Remediation of methane from the atmosphere; controlling methane emission from landfills, animal production facilities, etc.
• Removal of metals from aqueous solutions
• Removal of mercury from gaseous waste streams
• Production of nanoparticles from precious metals

]]>References:Stage2.pngDevelopment Stage:Desc0000.pngCraigForneyCommercialization Manager, Chemistry and Materials Sciencesceforney@iastate.edu515-294-4740Methylocystis Strain SB2 Materials and MethodsUtilityUnited States8,629,23913/198,6698/4/20111/14/20148/4/203112/8/201511/13/2017FalseMultimodal applications for mesoporous silica nanoparticles in contrast imaginghttp://isurftech.technologypublisher.com/technology/21064Description:
A novel multimodal nanomaterial contrast agent with unique capability for in vivo and in biomedical imaging has been developed. The particle is designed to elicit a significant signal compared to organs, tissues and cells examined with CT, MRI Echo as well Fluorescence Microscopy. This invention is the “Swiss Army knife” approach to contrast imaging techniques. The particle is based on a backbone of mesoporous silica nanoparticles (MSN), a 200 nm diameter particle with 3-5 nm pores that can be loaded with a drug or reagent of interest. The surface of MSN and/or the silica framework is covalently functionalized with one or more of the following materials: gadolinium oxide, gold, -CF3 functional groups, and/or a fluorophore such as FITC or Texas Red. These materials can then be detected with one or more of the following imaging modalities: magnetic resonance imaging, x-ray computed tomography, ultrasound/photoacoustic imaging, or fluorescence microscopy. The particles have the propensity to bind and gain entry into a variety of cells through nonspecific (engulfed) or specific (extracellular binding molecules) labeling methods. The particle can also selectively bind cells using receptor ligands, which make this useful to biomedical research as well as drug delivery. The particle’s versatility makes it a potentially powerful tool for both clinical and research purposes.

Advantage:
• Effective in vivo
• Inert material that is biocompatible

Application:
Biomedical imaging, biomedical research, drug delivery

References:
U.S. Patent Application 2015/0125398

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 08:45:16 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210644023Mon, 13 Nov 2017 10:23:39 GMTDescription:

]]>Advantage:

]]>Application:

]]>References:U.S. Patent Application 2015/0125398]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngCraigForneyCommercialization Manager, Chemistry and Materials Sciencesceforney@iastate.edu515-294-4740Healthcare| Imaging| Life SciencesFalseVisible Light Absorbing Photoremovable Protecting Groupshttp://isurftech.technologypublisher.com/technology/21063Summary:
Researchers at Iowa State University have developed photoremovable protecting groups (often referred to as “photocages”) that photoheterolyse in response to light in the visible spectrum.

Description:
Photoremovable protecting groups are chemical agents that provide control over the release of any number of reagents in a variety of environments. From bioagents (including active chemical compounds, nucleotides and other compounds) to ions, acids, bases, oxidants, etc., photoremovable protecting groups (PPGs, or alternately, photocages) are used to release these compounds in response to light. All commonly-used photocages respond to UV light. The use of visible light provides several distinct advantages, including depth of penetration in biological tissues, limited damage to biological tissue, researcher safety, and potential for use of multiple photocage-reagent combinations responsive to different light wavelengths in experimental design.

Advantage:
• Photochemical lysis responds to light absorption in the visible light range
• Can be tuned to different wavelengths of light so that multiple differently caged molecules could be released in response to different light sources
• Will work with a wide variety of biological and non-biological molecules

Application:
Laboratory reagent

References:
P.P. Goswami et al., “BODIPY-Derived Photoremovable Protecting Groups Unmasked with Green Light”, Journal of the American Chemical Society, 137, pp. 3783-3786, 2015.

Patent:
Patent(s) applied for

Stage3.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 08:45:14 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210634254Mon, 13 Nov 2017 10:23:39 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>References:P.P. Goswami et al., “BODIPY-Derived Photoremovable Protecting Groups Unmasked with Green Light”, Journal of the American Chemical Society, 137, pp. 3783-3786, 2015.]]>Patent:Patent(s) applied forStage3.pngDevelopment Stage:Desc0000.pngCraigForneyCommercialization Manager, Chemistry and Materials Sciencesceforney@iastate.edu515-294-4740FalseSoybean Genes for Enhanced Sudden Death Syndrome Resistancehttp://isurftech.technologypublisher.com/technology/21060Summary:
Endogenous soybean genes with potential to yield soybean varieties with improved resistance to sudden death syndrome (SDS) in soybeans.

Description:
ISU researchers have identified ten soybean genes with markedly reduced gene expression following infection by the fungus Fusarium virguliforme that causes sudden death syndrome in soybeans. The genes are being characterized for resistance to sudden death syndrome in transgenic soybeans and some of the genes look promising. If effective these findings may lead to the development of commercially important sudden death syndrome resistant soybean cultivars.

Advantage:
• Potential for enhanced resistance to soybean pathogens
• Widely accepted approach
• On of the genes shows multiple resistance to Fusarium, Aphids, and Mites

Application:
Plant breeding, Soybeans, Genetic engineering

Patent:
Patent(s) applied for

Group:
This technology is related to ISURF 4276: Soybean SDS Nonhost Resistance Genes Pss6, Pss21 & Pss25 and ISURF 4277: Peptides to Neutralize FvTox1 Sudden Death Syndrome Toxin FvTox1 in Soybeans

Stage2.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 07:58:25 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210604273Mon, 13 Nov 2017 10:23:38 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Patent:Patent(s) applied forGroup:ISURF 4276: Soybean SDS Nonhost Resistance Genes Pss6, Pss21 & Pss25 and ISURF 4277: Peptides to Neutralize FvTox1 Sudden Death Syndrome Toxin FvTox1 in Soybeans

]]>Stage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalsePeptides to Neutralize FvTox1 Sudden Death Syndrome Toxin FvTox1 in Soybeanshttp://isurftech.technologypublisher.com/technology/21059Summary:
Fusarium virguliforme FvTox1-interacting synthetic peptide sequences for enhancing foliar sudden death syndrome resistance in soybean.

Description:
This innovation relates to the field of genetic engineering of soybeans. Novel FvTox1 binding peptides encoding nucleic acid molecules, as well as the proteins encoded by such nucleic acids are disclosed as well as methods of conferring tolerance to sudden death syndrome (SDS) and the development of genetically modified plant cells with improved tolerance to SDS. Expression of these synthetic peptides is predicted to reduce photorespiration and increase photosynthesis, thus leading to higher yields. Transgenic soybeans expressing the synthetic peptides are available for evaluation.

Advantage:
• Enhanced tolerance to SDS
• Proof-of-concept in plants
• Transgenic soybeans available for evaluation
• Potential for increased photosynthesis


Application:
Development of SDS resistant soybean varieties.

Group:
This technology is related to ISURF 4273: Soybean Genes for Enhanced SDS Resistance and ISURF 4276: Soybean SDS Nonhost Resistance Genes Pss6, Pss21 & Pss25

References:
Wang B, Swaminathan S, Bhattacharyya MK (2015) Identification of Fusarium virguliforme FvTox1-Interacting Synthetic Peptides for Enhancing Foliar Sudden Death Syndrome Resistance in Soybean. PLoS ONE 10(12): e0145156. doi:10.1371/journal.pone.0145156

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Tue, 08 Dec 2015 07:58:25 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210594277Mon, 13 Nov 2017 10:23:37 GMTSummary:

]]>Description:

]]>Advantage:]]>

]]>Application:

]]>Group:ISURF 4273: Soybean Genes for Enhanced SDS Resistance and ISURF 4276: Soybean SDS Nonhost Resistance Genes Pss6, Pss21 & Pss25

]]>References:Wang B, Swaminathan S, Bhattacharyya MK (2015) Identification of Fusarium virguliforme FvTox1-Interacting Synthetic Peptides for Enhancing Foliar Sudden Death Syndrome Resistance in Soybean. PLoS ONE 10(12): e0145156. doi:10.1371/journal.pone.0145156

]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseMonoclonal Antibodies against a Novel Isoform of Human Protein Kinase C Deltahttp://isurftech.technologypublisher.com/technology/21053Description:
ISU researchers have developed highly specific monoclonal antibodies against human PKC δ. One of the antibodies of this invention (10F11B) is far superior to a widely-used commercial antibody. The researchers have used the 10F11B antibody to measure the PKC δ protein in primary mouse astrocytes and in mouse striatum and hippocampal tissue by Western blot analysis. In addition, the same antibody has been used for immunochemistry applications including identification of PKC δ in cell layers of the cerebellum.   The 10F11B hybridoma is available for licensing on a non-exclusive basis.

Advantage:
• Highly specific monoclonal antibody
• Superior to current commercially available antibody
• Suitable for ELISA, immunochemistry, and Western blot analysis

Application:
Research, Diagnostic Development

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 14:49:15 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210534423Mon, 13 Nov 2017 10:23:32 GMTDescription:

]]>Advantage:

]]>Application:]]>Stage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseStreptococcus suis Isolateshttp://isurftech.technologypublisher.com/technology/21052Description:
Streptococcus Suis is a pig pathogen that occasionally infects humans. Iowa State University is making available for non-exclusive licensing four Streptococcus Suis isolates with potential for research use, diagnostics, and development of vaccines. Both viruses  [A/Swine/ISUVDL11/05 (H3N2-cluster III) and A/Swine/ISUVDL12/05 (reassortant H1N1)] represent 2005 swine influenza viruses contemporary isolates of H1N1 and H3N2 subtypes that circulating in US swine populations at the time.

Advantage:
• Ready to use
• Adapted to growth in culture

Application:
Animal Health/ Vaccine Development/ Diagnostics

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 14:44:02 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210523342Mon, 13 Nov 2017 10:23:31 GMTDescription:Advantage:Application:Animal Health/ Vaccine Development/ DiagnosticsIntellectual Property:Tangible MaterialStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineFalse
Genetic Basis and Test for Severe Combined Immune Deficiency in Pigshttp://isurftech.technologypublisher.com/technology/21051Summary:
The genetic basis of Severe Combined Immune Deficiency (SCID) in pigs and tests that can be used to identify SCID pigs and SCID carriers have been established

Description:
ISU researchers previously identified and documented, for the first time, the presence of SCID in pigs. Additional research on the experimental mutant pig line developed at ISU  enabled the identification of the genomic region harboring the causative mutation. The discovery  of the mutation allowed the development of genetic tests that can be used to identify SCID pigs and SCID carriers. The identification and understanding of the genetic basis for the SCID mutation will allow further characterization of the SCID phenotype for animal disease and biomedical research, including research into the immune system, cancer research, the effects of disease, cell and tissue transplantation, and for testing of new vaccines and therapeutic agents for immuno-compromised individuals. SCID pigs provide a much better animal model for such purposes than the widely used SCID mice and, thus, development of this model could potentially be extremely useful for advancing biomedical research and drug discovery . 

Advantage:
• Rapid ID of SCID pigs in litters for biomedical research
• Tool for  genetic surveillance of commercial pig lines

Application:
Biomedical research

Group:
This technology is related to ISURF 3992:  Immunodeficient Pigs for Biomedical Research 

Stage3.png
Development Stage:

Desc0000.png

]]>
Mon, 07 Dec 2015 14:39:38 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210514044Mon, 13 Nov 2017 10:23:31 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Group:ISURF 3992:  Immunodeficient Pigs for Biomedical Research 

]]>Stage3.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineGenetic Test and Genetic Basis for SCID in pigsUtilityUnited States9,745,56114/592,5861/8/20158/29/20172/17/20359/8/201711/20/2017FalseChallenge Strains of Mycoplasma bovishttp://isurftech.technologypublisher.com/technology/21050Description:
There is a need to have highly pathogenic strains of Mycoplasma bovis to challenge cattle that are vaccinated with vaccine candidates against Mycoplasma bovis in order to test the efficacy of the vaccine candidates. ISURF is making available for licensing on a non-exclusive basis two Mycoplasma bovis strains (M23, 428E) suitable to help validate Mycoplasma bovis vaccine candidates and for diagnostics.  The strains were recovered from two different outbreaks of Mycoplasma bovis pneumonia and polyarthritis in Iowa cattle.  Description of one of the outbreaks has been published.  Description of the pathogenic potential of both strains has been presented at conferences.  One of the strains (M23) has been used as standard strain for cattle infection reports, and as wild-type to develop various mutants with gene disruptions or deletions.

Advantage:
• Well-characterized strains
• Suitable for diagnostics and vaccine validation

Application:
Research, Diagnostics, Vaccine Validation Studies

References:
Rosenbusch, R. F. Bovine mycoplasmosis. Proceedings of the 34th Annual Convention of the American Association of Bovine Practitioners, pp 49-52, Vancouver, British Columbia, 2001.

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 14:39:38 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210503876Mon, 13 Nov 2017 10:23:30 GMTDescription:

]]>Advantage:

]]>Application:

]]>References:Rosenbusch, R. F. Bovine mycoplasmosis. Proceedings of the 34th Annual Convention of the American Association of Bovine Practitioners, pp 49-52, Vancouver, British Columbia, 2001.Stage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseNeuroprotection by Mitochondria-targeted Metforminhttp://isurftech.technologypublisher.com/technology/21048Description:
Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades. Researchers at Iowa State University and Medical College of Wisconsin synthesized Mito-Met, a mitochondria-targeted analog of metformin and then evaluated the preclinical efficacy of Mito-Met in cell culture and MitoPark animal models of Parkinson’s disease. It was demonstrated that Mito-Met improved motor deficits in MitoPark mice and that it was a neuroprotective agent that exceedingly qualifies for in-depth preclinical efficacy and toxicology evaluations for treating mitochondrial diseases including Parkinson’s disease.

Advantage:
• Increases the survival of dopaminergic neurons in cell culture and in a mouse model of Parkinson’s disease
• Based on FDA-approved low-toxicity drug
• Chemical modifications increased its affinity to the intended mitochondrial target
• Addresses a high value market
• Effective at very low doses

Application:
Human Therapeutics, Treatment of Parkinson’s disease

Patents:
Patent(s) Applied For

Stage2.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 14:13:58 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210484417Mon, 13 Nov 2017 10:23:28 GMTDescription:

]]>Advantage:

]]>Application:

]]>Patents:Patent(s) Applied ForStage2.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesFalseMethods and Compositions for Backbone-Free Low Transgene Copy Transgenic Plantshttp://isurftech.technologypublisher.com/technology/21046Summary:
The innovation is an improvement on the use of Agrobacterium mediated gene transfer for the transformation of plants.

Description:
Iowa State University researchers working with Purdue University researchers have developed new approaches to generate transgenic plants that have no transformation vector backbone in plants having transgenes at a low copy number. Agrobacterium strains with T-DNA integrated into the chromosomal DNA of the Agrobacterium are shown to reduce the copy number and backbone sequences. The inventors have also developed chromosomal integration vectors to integrate T-DNA into a specific (picA/pgl) locus in the chromosome of Agrobacterium. Agrobacterium strains available for licensing are: EHA101, EHA105, GV3101, and LBA4404. The technology and associated materials are available for licensing on a non-exclusive basis.

Advantage:
• Proven technology
• Materials available
• Creation of high-quality transgenic plants

Application:
Construction of transgenic plants

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 14:06:08 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210463546Mon, 13 Nov 2017 10:23:27 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:Construction of transgenic plantsStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesBackbone-Free Low Transgene Copy Transgenic PlantsUtilityUnited States8,334,42812/514,1805/8/200912/18/201212/19/201612/7/201511/13/2017FalseSwine Influenza Viruses for Vaccine and Diagnosticshttp://isurftech.technologypublisher.com/technology/21042Summary:
Iowa State University is making available for non-exclusive licensing two swine influenza A virus isolates with potential for research use, diagnostics, and development of vaccines. The viruses isolated in 2005 originated from pigs exhibiting respiratory stress. Both viruses  [A/Swine/ISUVDL11/05 (H3N2-cluster III) and A/Swine/ISUVDL12/05 (reassortant H1N1)] represent 2005 swine influenza viruses contemporary isolates of H1N1 and H3N2 subtypes circulating in US swine populations.

Advantage:
• Ready to use
• Adapted to growth in culture

Application:
Animal Health/Vaccine Development/Diagnostics

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 13:27:44 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210423345Mon, 13 Nov 2017 10:23:25 GMTSummary:

]]>Advantage:

]]>Application:

]]>Intellectual Property:]]>Stage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineFalseRoom Temperature Ferromagnetic Gd5Si4 MRI Contrast Agenthttp://isurftech.technologypublisher.com/technology/21035Summary:
Iowa State University and Ames Laboratory researchers have developed a method to create gadolinium silicide nanoparticles which retain ferromagnetic properties at room temperature.

Description:
This innovative method creates Gd5Si4 nanoparticles that retain the ferromagnetic properties of the bulk material at room temperature. These nanoparticles may be useful as a MRI contrast agent or for other applications that would benefit from materials that highly respond to a magnetic field, such as transcranial magnetic stimulation, MRI thermometry, and hyperthermic cancer treatment.

The gadolinium-based ferromagnetic particles are produced using ball milling in an inert atmosphere. The resultant particles retain an order of magnitude greater magnetization compared to conventionally prepared gadolinium particles. Ordinary preparation methods destroy the ordered structure required for ferromagnetism, resulting in materials with the much weaker paramagnetic properties - ferromagnetic materials have a high susceptibility to magnetization when subjected to a magnetic field and retain that magnetization after the field is removed; paramagnetic materials respond to a magnetic field but do not retain any magnetization when removed from the field.

Advantage:
• Increased magnetic properties compared to existing MRI contrast agents

Application:
MRI contrast agent; transcranial magnetic stimulation, hyperthermic cancer treatment

References:
1. "Investigation of Room Temperature Ferromagnetic Nanoparticles of Gd5Si4”, R.L. Hadimani et al., IEEE Transactions on Magnetics, 51, 2504104, 2015.  DOI: 10.1109/TMAG.2015.2446774

2. H. A. El-Gendy, S. M. Harstad, V. Vijayaragavan, S. Gupta, V. K. Pecharsky, J. Zweit and R. L. Hadimani "Ferromagnetic Gd5Si4 Nanoparticles as T2 Contrast Agents for Magnetic Resonance Imaging" IEEE Magnetics Letters, 2017, 8, 1507504. DOI 10.1109/lmag.2017.2728503

Patent:
Patent(s) applied for

Stage1.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 11:38:09 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210354379Mon, 13 Nov 2017 10:23:22 GMTSummary:

]]>Description:

The gadolinium-based ferromagnetic particles are produced using ball milling in an inert atmosphere. The resultant particles retain an order of magnitude greater magnetization compared to conventionally prepared gadolinium particles. Ordinary preparation methods destroy the ordered structure required for ferromagnetism, resulting in materials with the much weaker paramagnetic properties - ferromagnetic materials have a high susceptibility to magnetization when subjected to a magnetic field and retain that magnetization after the field is removed; paramagnetic materials respond to a magnetic field but do not retain any magnetization when removed from the field.

]]>Advantage:

]]>Application:

]]>References:1. "Investigation of Room Temperature Ferromagnetic Nanoparticles of Gd5Si4”, R.L. Hadimani et al., IEEE Transactions on Magnetics, 51, 2504104, 2015.  DOI: 10.1109/TMAG.2015.2446774

2. H. A. El-Gendy, S. M. Harstad, V. Vijayaragavan, S. Gupta, V. K. Pecharsky, J. Zweit and R. L. Hadimani "Ferromagnetic Gd5Si4 Nanoparticles as T2 Contrast Agents for Magnetic Resonance Imaging" IEEE Magnetics Letters, 2017, 8, 1507504. DOI 10.1109/lmag.2017.2728503

]]>Patent:Patent(s) applied forStage1.pngDevelopment Stage:Desc0000.pngCraigForneyCommercialization Manager, Chemistry and Materials Sciencesceforney@iastate.edu515-294-4740Ames Laboratory| Healthcare| Imaging| Life Sciences| MaterialsFalseDroplet Actuator and Methods of Droplet Manipulationhttp://isurftech.technologypublisher.com/technology/21034Summary:
Iowa State University researchers have developed a portable system to perform droplet operations such as transport, mixing, merging, dispensing, and particle separation from liquid droplets. The system uses two electrical motors to tilt a planar platform at pre-specified angles, thereby allowing multiple droplets to move in pre-decided patterns.

Description:
The invention is a portable system to perform droplet manipulations such as transport, mixing, dispensing, and particle separation from liquid droplets.  The novelty is in the methods of moving droplets using gravitational force and mechanical jerks.  The design of hydrophilic patterns, along with the gravitational and mechanical tilting of the platform, help move the droplets.  The utility of this invention is the ease of use and low-cost compared to the existing technology being used today.  This system can help automate a diverse range of applications in molecular diagnostics of physiological samples.

Advantage:
• Portable, cost efficient design compared to currently available automated liquid handling systems
• Uses mechanical jerks and gravity to move droplets vs. current systems which use high electrical voltages, laser beams or vibrations from sound generating devices
• Utilizes unique techniques of printing patterns of specific shapes and sizes on a low-cost transparency film that has been treated to provide hydrophobic and hydrophilic areas

Application:
Immunology, protein chemistry, biomarker identification and molecular diagnosis of physiological samples

Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 11:38:08 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210344313Mon, 13 Nov 2017 10:23:21 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngJayBjerkeCommercialization Manager, Engineeringjbjerke@mail.iastate.edu515-294-4740FalseNovel Senecavirus A as Etiology of Vesicular Disease and Methods to Propagate the Virus in Vitrohttp://isurftech.technologypublisher.com/technology/21032Summary:
Iowa State University researchers have identified, purified, and characterized cell culture-derived isolates of Senecavirus. A. The full genome sequence of the new isolates revealed that the isolates are genetically distinct from previously known Senecavirus A viruses.

Description:
Genetic changes/mutations have made the virus virulent, thus accounting for the 2015 vesicular disease outbreak in show and commercial pigs which have been seen in a number of States in the Midwest including IA, SD, IL, IN, MO, MN. From the rapid spreading and frequent identification of the virus, researchers concluded that prevention and control measures will be needed and that the isolates have value as tangible property for biologics and diagnostics. The isolates have been propagated continuously in culture to high titer at ISU and the idiopathic vesicular disease was reproduced with one isolate (in collaboration with the USDA). Propagation of the virus to a high titer will aid in producing vaccines and diagnostic reagents.

Advantage:
• Distinct new viral strains
• Full genome sequence available
• High titer will aid in producing vaccines and diagnostic reagents
• Addresses a niche market

Application:
Therapeutic / Vaccine Development

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 11:10:38 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210324416Mon, 13 Nov 2017 10:23:20 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:Therapeutic / Vaccine DevelopmentIntellectual Property:Tangible MaterialStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseNovel Senecavirus A as Etiology of Vesicular Disease and Methods to Propagate the Virus in Vitrohttp://isurftech.technologypublisher.com/technology/21031Summary:
Iowa State University researchers have identified, purified, and characterized cell culture-derived isolates of Senecavirus. A. The full genome sequence of the new isolates revealed that the isolates are genetically distinct from previously known Senecavirus A viruses.

Description:
Genetic changes/mutations have made the virus virulent, thus accounting for the 2015 vesicular disease outbreak in show and commercial pigs which have been seen in a number of States in the Midwest including IA, SD, IL, IN, MO, MN. From the rapid spreading and frequent identification of the virus, researchers concluded that prevention and control measures will be needed and that the isolates have value as tangible property for biologics and diagnostics. The isolates have been propagated continuously in culture to high titer at ISU and the idiopathic vesicular disease was reproduced with one isolate (in collaboration with the USDA). Propagation of the virus to a high titer will aid in producing vaccines and diagnostic reagents.

Advantage:
• Distinct new viral strains
• Full genome sequence available
• High titer will aid in producing vaccines and diagnostic reagents
• Addresses a niche market

Application:
Therapeutic / Vaccine Development

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 11:10:37 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210314422Mon, 13 Nov 2017 10:23:19 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Intellectual Property:Tangible MaterialStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseMicroscale Tentacle Actuatorhttp://isurftech.technologypublisher.com/technology/21029Description:
ISU researchers have invented a soft material-based manipulator for delicate, fragile microscale objects. It is based on a thin-walled elastomeric microtube with an asymmetric wall thickness distribution and one end closed. Upon applying air pressure from the open end, the microtube becomes elongated non-uniformly, bending towards the thick-walled side. This type of bending, however, is often insufficient to induce a spiraling which mimics the coiling motion of biological tentacles, such as those of the octopus. To amplify the bending into multi-turn spiraling, we installed a small extra thickness (i.e., hump) to the exterior of the microtube. When the size and position of the hump were adequate, the microtube could accomplish multi-tum spiraling which is ideal for winding around small objects and scoop them up. This type of conformal spiraling motion is non-destructive since it does not involve squeezing and will be useful for safe handling of cell aggregates, eggs, or biological tissues that are highly fragile.

Advantage:
• Can handle soft, fragile micro-objects that is not offered today
• Capable of grabbing objects as small as ~ 185 µM with a grabbing force of ~ 0.78 mN
• Unique fabrication techniques of the thin, highly deformable microtubes

Application:
Biological microelectromechanical systems (bio-MEMS)

References:
Microrobotic tentacles with spiral bending capability based on shape-engineered elastomeric microtubes


Patent:
Patent(s) applied for

Stage2.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 10:17:50 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210294387Mon, 13 Nov 2017 10:23:17 GMTDescription:

]]>Advantage:

]]>Application:

]]>References:Microrobotic tentacles with spiral bending capability based on shape-engineered elastomeric microtubes

]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:Desc0000.pngJayBjerkeCommercialization Manager, Engineeringjbjerke@mail.iastate.edu515-294-4740FalseDiffusion Barrier Vaccine Devicehttp://isurftech.technologypublisher.com/technology/21025Summary:
Iowa State University researchers have developed an implanted vaccine device designed to generate life-long antibody titers. The basis of the innovation is the slow release of an antigen embedded in a polymeric matrix. Antigen release is a function of the level of circulating antigen-specific antibodies.  By sensing the antibody levels, the device self-regulates antigen release thus ensuring antigen availability for continued antibody production.

Description:
The technology is a three-stage vaccine device, where stage 1 consists of vaccination with the antigen of interest using soluble adjuvant-based delivery. Stage two is a boost delivered using bio-erodible nanoparticles. Stage three is the “smart release” of vaccine where vaccine release is linked to antibody levels. The smart release utilizes a fibrillary matrix where, if immune complexes of antibody and antigen are present, they will be hindered from escaping the depot. If antibody levels fall, the complexes are dissociated and the antigen is small enough to escape from the vaccine depot. This provides a booster-like response leading to increased antibody production.

Advantage:
• Enables immune-regulated release of vaccine
• May reduce or eliminate the need for future booster vaccinations
• May be used with a number of various vaccines
• Addresses a very large market

Application:
Animal Health / Vaccine Development

Patent:
Patent(s) applied for

Stage1.png
Development Stage:

Desc0000.png

]]>Mon, 07 Dec 2015 10:17:48 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/210254256Mon, 13 Nov 2017 10:23:15 GMTSummary:

]]>Description:

]]>Advantage:

]]>Application:

]]>Patent:Patent(s) applied forStage1.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineFalseHaploid Inducing Genotype for Field and Specialty Cornhttp://isurftech.technologypublisher.com/technology/20090Summary:
Iowa State University researchers have developed a new haploid inducer for specialty maize that can overcome dent sterility used in popcorn and organic breeding programs, as well as two selectable marker – R1-nj and Pl1 – for haploid selection.

Description:
Inbred corn lines have two identical copies of their genome, and are valuable breeding resources since offspring are identical to their parent. Since offspring of hybrids are genetically segregating, hybrid seed needs to be generated from genetically stable, parental inbred lines. Development of traditional corn inbred lines starts from heterozygous plants and requires continued self-pollination, which takes five to eight generations before an inbred line is pure enough to be combined with another inbred line to create a hybrid. Doubled haploid (DH) technology can be used to produce pure, inbred corn lines in just two generations, since the initial “haploid” offspring contain only a single genome instead of two, which is then doubled in this DH procedure.  So-called inducer lines are used as pollinators in the DH approach. 

The DH technology  has found broad acceptance in corn breeding. Specialty breeders such as popcorn and sweet corn breeders and organic growers use the dent sterility trait to prevent undesired field corn from pollinating their lines. The specialty inducer developed can be used for all donor materials, and especially in popcorn and organic breeding programs that use dent sterility (Ga1), to prevent uncontrolled pollinations with genetically modified field corn.
The inducer has two selectable markers for haploid identification: the kernel color marker R1-nj that allows haploid selection in the seed, and the root color marker Pl1 that allows haploid selection after germination in young seedlings. Inducer lines are adapted to the Midwest growing season and have comparable induction rates to previously released inducer lines.

Advantages:
• Simple dual seed color and root color selection increases the number of true positives.
• Haploid inducing rates comparable to European inducers but better suited to Midwest corn growing season
• Able to overcome dent sterility (Ga1)

Application:
Plant Breeding


Intellectual Property:
Tangible Property

Group:
This technology is related to ISURF #4065: Midwest Adapted Haploid Inducer for Maize

Stage4.png
Development Stage:
Lines will be available in the Fall of 2015

Desc0000.png

]]>Fri, 07 Aug 2015 07:09:34 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/200904099Mon, 13 Nov 2017 10:22:52 GMTSummary:

]]>Description:

The DH technology  has found broad acceptance in corn breeding. Specialty breeders such as popcorn and sweet corn breeders and organic growers use the dent sterility trait to prevent undesired field corn from pollinating their lines. The specialty inducer developed can be used for all donor materials, and especially in popcorn and organic breeding programs that use dent sterility (Ga1), to prevent uncontrolled pollinations with genetically modified field corn.
The inducer has two selectable markers for haploid identification: the kernel color marker R1-nj that allows haploid selection in the seed, and the root color marker Pl1 that allows haploid selection after germination in young seedlings. Inducer lines are adapted to the Midwest growing season and have comparable induction rates to previously released inducer lines.

]]>Advantages:Application:Plant BreedingIntellectual Property:Tangible PropertyGroup:ISURF #4065: Midwest Adapted Haploid Inducer for Maize

]]>Stage4.pngDevelopment Stage:Lines will be available in the Fall of 2015Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseQTL Regulating Ear Productivity Traits in Maizehttp://isurftech.technologypublisher.com/technology/20089Summary:
Methods to increase ear productivity in maize

Description:
Increased grain yields should translate into improved productivity and profitability for farmers; hence, traits that improve yield should be desirable in seed sold to farmers. This invention identifies DNA markers associated with the following ear productivity traits in maize:

• Cob length
• Cob weight
• Cob diameter
• Kernel count
• Kernel weight
• Kernel row number

The ear productivity DNA markers of this invention might form the basis of hybrid seed with advanced genetics, and could be bundled with transgenic traits, or sold as conventional seed.

Advantage:
• Potential to develop maize with increased productivity
• Markers easily tractable using modern molecular techniques
• Applicable to conventional or genetically modified seeds

Stage4.png
Development Stage:
The patented methodologies are ready to be applied for the commercial development of improved maize

Desc0000.png

]]>Fri, 07 Aug 2015 06:46:51 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/200893797Mon, 13 Nov 2017 10:22:51 GMTSummary:

]]>Description:

• Cob length
• Cob weight
• Cob diameter
• Kernel count
• Kernel weight
• Kernel row number

The ear productivity DNA markers of this invention might form the basis of hybrid seed with advanced genetics, and could be bundled with transgenic traits, or sold as conventional seed.]]>Advantage:Stage4.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesQTL Regulating Ear Productivity Traits in MaizeUtilityUnited States8,779,23313/180,9867/12/20117/15/201410/25/20318/7/201511/20/2017FalseMouse Monoclonal Anti Clostridium Perfringens Type D epsilon Toxin Antibody (Clone# 4D6)http://isurftech.technologypublisher.com/technology/19981Summary:
The 4D6 monoclonal antibody can detect nanogram quantities by Western blotting of both the Clostridium perfringens epsilon proto-toxin as well as the activated toxin

Description:
The epsilon toxin is one of 12 protein toxins produced by Clostridium perfringens, a Gram positive, anaerobic spore-forming rod. There are five strains of C. perfringens, designated A through E. Each strain produces a unique spectrum of toxins. The epsilon toxin is made by types B and D. This toxin is a pore-forming protein; it causes potassium and fluid leakage from cells. In addition to the epsilon toxin, Clostridium perfringens type D strains produce alpha toxin and type B strains produce alpha and beta toxins. C. perfringens type B causes severe enteritis in young calves, foals, lambs and piglets. Type D causes enterotoxemia in sheep and goats and, on rare occasions, in cattle. All five strains can infect wounds in any species.
The innovation available for licensing is a monoclonal antibody (4D6) that can be used as a diagnostic tool to detect Epsilon toxin, a classified bio-terrorism agent. The researchers have observed in the lab that His-tagged epsilon toxoid forms spontaneous SDS-resistant multimers. 4D6 can also detect multimer forms of protein. 4D6 can also detect, native un-cleaved ETX proto-toxin as well trypsin cleaved fragments that have higher electrophoretic mobility.

Advantage:
• Probably the only D epsilon toxin monoclonal antibody available commercially
• Can detect as little as 625pgs of recombinant  epsilon mutant toxoid.
• Easy detection with anti-mouse-IgG-HRP

Application:
Detection of the Clostridium perfringens epsilon toxin

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:

Desc0000.png

]]>Mon, 20 Jul 2015 14:29:28 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/199814281Mon, 13 Nov 2017 10:22:49 GMTSummary:

]]>Description:The innovation available for licensing is a monoclonal antibody (4D6) that can be used as a diagnostic tool to detect Epsilon toxin, a classified bio-terrorism agent. The researchers have observed in the lab that His-tagged epsilon toxoid forms spontaneous SDS-resistant multimers. 4D6 can also detect multimer forms of protein. 4D6 can also detect, native un-cleaved ETX proto-toxin as well trypsin cleaved fragments that have higher electrophoretic mobility.

]]>Advantage:

]]>Application:

]]>Intellectual Property:Tangible MaterialStage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Healthcare| Life Sciences| Veterinary MedicineFalseSSM Sequence Modelshttp://isurftech.technologypublisher.com/technology/19750Description:
The SSM Sequence Models (SSMs) provide a mechanism for analyzing information and the relationships that may exist for that information in a much more computationally efficient manner than any current mechanisms in use today.  In its simplest terms, the SSMs can provide a spell checker that can identify a misspelled word and provide the correct spelling of the actual intended word.  In some of its more complex uses, the SSMs can provide voice recognition and speech synthesis, robotic learning using associative and auto associative memory, object recognition, Internet searching and categorization of information, and methods of recognizing, classifying, and analyzing biological sequences such as protein and DNA sequences–all with very high accuracy–to name a few.  Indeed, SSMs may be used in any application that currently use Hidden Markov Models (HMMs), and will provide these systems with an increase in speed and accuracy, and a decrease in the computing power that is needed to accomplish the specific task.  Further, unlike HMMs that often must be trained off line due to their computational complexity (particularly as the sequences involved become large), the SSMs can be trained in real time.  Simply put, SSMs are much more efficient and effective than HMMs in performing all of the tasks for which HMMs are currently used, and therefore provide an elegant replacement.

Advantage:
• Highly accurate and efficient
• Reduces computing power required for completing analysis
• Trainable in real-time
• Parallelizable

Application:
Pattern or Sequence Recognition Applications Including, but Not Limited to, Voice Recognition, Objection Recognition, Computational Biology, Robotic Learning, Search, and Classification

Patent:
Patent(s) applied for

Stage2.png
Development Stage:
A prototype implementation for speech recognition demonstrating high accuracy and reduced computing power has been completed.

Desc0000.png

]]>Thu, 11 Jun 2015 13:19:45 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/197503990Mon, 13 Nov 2017 10:22:45 GMTDescription:

]]>Advantage:

]]>Application:

]]>Patent:Patent(s) applied forStage2.pngDevelopment Stage:

]]>Desc0000.pngJayBjerkeCommercialization Manager, Engineeringjbjerke@mail.iastate.edu515-294-4740FalseHybridoma Cell Lines for Mycoplasma bovishttp://isurftech.technologypublisher.com/technology/19581Description:
Two mouse/mouse stable hybridomas (87, 163) have been developed against M. bovis strain M23. M. bovis is associated with a variety of bovine diseases including arthritis and pneumonia of calves and young cattle, mastitis, and genital tract infections. It is considered the most virulent bovine mycoplasma in the US. Ascite fluid from these two hybridoma cells can be use in formalin-fixed, paraffin-embedded tissues and is highly specific in ELISA, IFA, and immunoblot analyses to six strains of M. bovis (M23, Emm, Bat, 1315, M66, and M84) originating from cases of bovine pneumonia or mastitis. They show no cross-reactivity with other bovine mycoplasma species often encountered in the US, Canada, and Europe. These species include M. dispar (SDO), M. alkalescens (PG31), M. bovirhinus (CS260), M. arginini (630), M. bovuculi (FS8-7), M. bovigenitalium (ATCC 14173), M. verecundum (ATCC 27862), andM. canadense (275C). Acite fluid from MYB 87 reacts with M. agalactiae (GM 139), a rare sheep and goat pathogen highly related to M. bovis, in IFA tests but not in ELISA. Ascite fluid from MYB 163 does not react with M. agalactiae. MYB 63 is of IgG1 Kappa isotype, while MYB 87 is of IgM Kappa isotype. These hybridomas should be useful in the diagnosis and detection of M. bovis and its related diseases.

Stage0.png

Desc0000.png

]]>Fri, 22 May 2015 14:32:59 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/195811908Mon, 13 Nov 2017 10:22:39 GMTDescription:]]>Stage0.pngDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740False
Soybeans Rich in Sulfur-Containing Amino Acids for Enhanced Nutritional Valuehttp://isurftech.technologypublisher.com/technology/19579Summary:
An Iowa State University researcher has developed a line of soybeans that is enriched in sulfur-containing amino acids.

Description:
Soybean seeds, while high in protein, are deficient in the two sulfur-containing amino acids, methionine and cysteine.  As a result, livestock growers spend millions of dollars annually to supplement soybean meal with methionine since cysteine cannot be synthesized de novo by animals and dietary methionine can be readily converted to cysteine.  To overcome this drawback, an ISU researcher has developed the first soybean seed line that is enriched in these sulfur-containing amino acids.  This soybean line thus has utility for enhancing the nutritional value of soy seed used as the basis for livestock feed or for food products for human consumption.  In addition, the soybean line was developed using a standard mutagenic procedure followed by traditional breeding methods, and thus is not genetically modified.

Advantage:
• Economical (eliminates the need for supplementing livestock rations with sulfur-containing methionine)
• Stable (analysis indicates that the line is homozygous for elevated seed sulfur concentration)

Application:
Soybean-based livestock feed and food products.

References:
"Selection of Soybean Mutants with Increased Concentrations of Seed Methionine and Cysteine”, John Imsande, 2001, Crop Science 41:510-515

Stage0.png
Development Stage:
A soybean line that is over 10% enriched for sulfur-containing amino acids has been developed, and ISU is seeking partners interested in its commercialization.

Desc0000.png

]]>
Fri, 22 May 2015 14:32:57 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/195792543Mon, 13 Nov 2017 10:22:37 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:"Selection of Soybean Mutants with Increased Concentrations of Seed Methionine and Cysteine”, John Imsande, 2001, Crop Science 41:510-515

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalsepH-Sensitive Methacrylic Copolymer Gelshttp://isurftech.technologypublisher.com/technology/19578Description:
Iowa State University and Ames Laboratory researchers have developed an invention which provides novel gel forming methacrylic blocking copolymers that exhibit cationic pH-sensitive behavior as well as good water solubility. The copolymers are constructed by polymerization of tertiary amine methacrylate with either a (poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) polymer, such as the commercially available Pluronic( polymers, or a poly(ethylene glycol) polymer. The polymers may be use for drug and gene delivery, protein separation, as structural supplements, and more.

Advantage:
• These copolymers are water-soluble, pH sensitive and capable of thermoreversible gelation near physiological temperatures.

Application:
* Drug delivery * Gene delivery * Protein separation * Structural supplements

Stage1.png
Development Stage:
Synthesis routes have been defined and materials have been produced, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Fri, 22 May 2015 14:32:56 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/195782954Mon, 13 Nov 2017 10:22:36 GMTDescription:

]]>Advantage:Application:* Drug delivery * Gene delivery * Protein separation * Structural supplementsStage1.pngDevelopment Stage:Synthesis routes have been defined and materials have been produced, and ISU is seeking partners interested in commercializing this technology.Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Ames Laboratory| Healthcare| Life Sciences| Materials| Veterinary MedicinepH-Sensitive Methacrylic Copolymer Gels and the Production ThereofUtilityUnited States7,217,77610/366,8642/14/20035/15/20072/14/20235/22/201511/13/2017False"September Sun" Seaside Alder Cultivar (Alnus maritima)http://isurftech.technologypublisher.com/technology/19577Summary:
Iowa State University researchers have developed a new seaside alder cultivar, ‘September Sun’.

Description:
Seaside alder (Alnus maritima) is rare native species in North America.  ISU researchers have developed the first cultivar of seaside alder, ‘September Sun’, that is suitable for use as a nursery crop.  This rapid growing and easy to propagate cultivar is an ornamentally superior genotype and an appealing autumn-blooming landscape shrub.  In addition, this shrub associates with nitrogen-fixing bacteria—unlike almost all other shrub species—which allows the plants to grow on very poor soils and to improve soil quality for other plants.  ‘September Sun’ is also highly tolerant of flooded soils, and helps reduce soil erosion along streams and other riparian areas, making it ideal for landscape restoration projects involving erosion control and wetland remediation.
In various field trials, including one with over 1000 plants and one with a three year growth period, ‘September Sun’ was demonstrated to be the most densely foliated, symmetrical, and rapidly growing seaside alder genotype.

Advantage:
• Fast growing and symmetrical, with attractive foliage and better autumn color than other alders
• Suitable for use in USDA hardiness zones 4a through 8b
• Blooms mid-August through late September
• Able to thrive in wet soil and more drought resistant than other North American alders
• Thrives in nitrogen-poor soil
• Easy to propagate

Application:
Ornamental Landscaping and Environmental Restoration

References:
September Sun’. Seaside Alder, an Autumn-blooming Shrub Native to North America", William R. Graves and James A. Schrader, 2004, HortScience 39:438-439.

Stage0.png
Development Stage:


Bare root plants are currently available.

Desc0000.png

]]>Fri, 22 May 2015 14:32:56 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/195773028Mon, 13 Nov 2017 10:22:35 GMTSummary:

]]>Description:
In various field trials, including one with over 1000 plants and one with a three year growth period, ‘September Sun’ was demonstrated to be the most densely foliated, symmetrical, and rapidly growing seaside alder genotype.

]]>Advantage:

]]>Application:

]]>References:September Sun’. Seaside Alder, an Autumn-blooming Shrub Native to North America", William R. Graves and James A. Schrader, 2004, HortScience 39:438-439.

]]>Stage0.png

]]>Bare root plants are currently available.Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesSeaside Alder Named "September Sun"UtilityUnited StatesPP18,10110/719,16411/22/200310/2/20071/22/20245/22/201511/21/2017FalseHybridoma Cell Lines for the Production of Monoclonal Antibodies Against Mycoplasma Hyopneumoniahttp://isurftech.technologypublisher.com/technology/19575Description:
Hybridoma cell lines F1B6 and F2G5 produce monoclonal antibodies which are unique in their ability to inhibit the in vitro adherence of M. hyopneumoniae to swine cilia. The tracheal cilia are the natural targets to which the mycoplasma binds during in vivo infection. The antibodies are important in the characterization of M. hyopneumoniae isolates by immunoblotting and adherence inhibition, and in purification of M. hyopneumoniae adhesins

Application:
- Veterinary diagnostics
- Vaccine quality control
The cell lines are available for non-exclusive licensing.

Intellectual Property:
Tangible material

Stage4.png
Development Stage:

Desc0000.png

]]>Fri, 22 May 2015 13:25:36 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/195752050Mon, 13 Nov 2017 10:22:35 GMTDescription:]]>Application:- Vaccine quality control
The cell lines are available for non-exclusive licensing.]]>
Intellectual Property:

]]>Stage4.pngDevelopment Stage:Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseAn Efficient DNA-Based Viral Gene Silencing Vector System for Soybean Functional Genomicshttp://isurftech.technologypublisher.com/technology/19386Summary:
Iowa State University researchers have developed an improved genetic tool for researching and understanding soybean genomics.

Description:
Virus-induced gene silencing (VIGS) is a new approach to so-called reverse genetics.  Using this technology, the expression of a known gene (or sequence) is altered and the resulting effect on plant phenotype is investigated.  VIGS is being increasingly used as a reverse genetics tool to study and identify functions of specific plant genes, especially in plants such as soybean that are refractory to other methods, such as transformation.  While RNA-based VIGS vectors have been developed for investigating gene function(s) in soybean, they are subject to RNA degradation, are not facile to manipulation, require in vitro RNA transcription, and are costly and time consuming.  As a result, these systems are not suitable for high-throughput genomics applications.  To overcome these drawbacks, ISU researchers have developed a highly reliable soybean gene expression and silencing vector. This second generation improvement over a previously described system is based on DNA inoculation and uses a Cauliflower mosaic virus (CaMV) promoter driven Bean pod mottle virus (BPMV) vector. Because the DNA-based BPMV vector is designed to silence multiple genes using a single construct, simultaneous testing of different combinations of genes to address questions related to genetic redundancy or epistasis is possible.  In addition, the vector can be used in soybean to validate the function of Arabidopsis gene homologues.

Advantage:
• Amenable to high through-put gene manipulation
• Highly efficient: obviates the need for in vitro transcription and infection using unstable RNA inoculation
• Enables silencing of multiple genes using a single construct
• Facilitates functional validation of Arabidopsis gene homologues
• Economical: eliminates the need for chemical stabilization of transcribed RNA

Application:
Soybean functional genomics

References:
C. Zhang, C. Yang, S. Whitham, J. Hill. "Development and Use of an Efficient DNA-Based Viral Gene Silencing Vector for Soybean". Molecular Plant-Microbe Interactions Journal. 22(2):123. 2009.

Stage2.png
Development Stage:
Highly reliable and efficient silencing of a variety of soybean genes, including those required for protein translation, defense signaling pathways, cytoskeleton, and roots, has been demonstrated.  The utility of the DNA-based BPMV VIGS vector in characterizing gene function has been shown using soybean homologues of Arabidopsis defense signaling pathways.

Desc0000.png

]]>Wed, 13 May 2015 11:03:21 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193863585Mon, 13 Nov 2017 10:22:05 GMTSummary:

]]>Description:To overcome these drawbacks, ISU researchers have developed a highly reliable soybean gene expression and silencing vector. This second generation improvement over a previously described system is based on DNA inoculation and uses a Cauliflower mosaic virus (CaMV) promoter driven Bean pod mottle virus (BPMV) vector. Because the DNA-based BPMV vector is designed to silence multiple genes using a single construct, simultaneous testing of different combinations of genes to address questions related to genetic redundancy or epistasis is possible.  In addition, the vector can be used in soybean to validate the function of Arabidopsis gene homologues.

]]>Advantage:Application:

]]>References:C. Zhang, C. Yang, S. Whitham, J. Hill. "Development and Use of an Efficient DNA-Based Viral Gene Silencing Vector for Soybean". Molecular Plant-Microbe Interactions Journal. 22(2):123. 2009.

]]>Stage2.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740BPMV-Based Viral Constructs Useful for VIGs and Expression of Heterologous Proteins in LegumesUtilityUnited States8,569,57912/927,57911/18/201010/29/201311/18/20305/13/201511/21/2017FalsePICKY: An Optimal Oligonucleotide Design and Analysis Toolhttp://isurftech.technologypublisher.com/technology/19385Summary:
Iowa State University researchers have developed a software tool that makes designing oligo probes for microarrays, or gene chips, easier, faster and with the highest quality. It also analyzes existing probes to detect potential cross-hybridization sites for trouble shooting, data analysis improvement or discovery

Description:
DNA microarrays have enabled detailed studies on gene expression, and are used in drug discovery research, comparative genomics, high throughput screening, diagnostics, and other applications.  However, the design of microarrays is crucial for maximizing experimental results.  To facilitate the design of oligonucleotide (oligos) probes used in microarrays, an ISU researcher has developed PICKY, a software tool for selecting optimal oligos.  PICKY allows the rapid and efficient determination of gene-specific oligos based on a given gene set, and can be used for large, complex genomes, such as human, rice or maize. PICKY can also be used to analyze existing microarray probes and evaluate their design quality. Because PICKY uses rigorous whole genome-based thermodynamic screening to identify hydrogen binding sites, it can be utilized for siRNA (short interference RNA) design for gene knockout applications and for discovery of natural miRNA (microRNA) targets. Non-exclusive free licenses are available for the 32-bit version of PICKY; the 64-bit version of PICKY, which allows bigger gene sets to be analyzed, is freely available to nonprofit users using it for non-commercial purposes, but commercial users will need to pay a licensing fee to license 64-bit version of PICKY for commercial use.

Advantage:
• Rapid (gene probes sets can be designed in only minutes or hours compared to other design tools that take days or weeks for some large genomes)
• Accurate (PICKY considers thermodynamics when selecting oligos, not just sequence similarity) 
• Versatile (may be used to design arrays and siRNAs or to analyze the quality of existing arrays)
• Independent (as a stand-alone program that works on all major computing platforms; PICKY does not require any third party software program to operate)

Application:
Microarray design; oligonucleotide probe and primer design; existing microarray re-analysis; siRNA Design

References:
1: “Shared probe design and existing microarray reanalysis using PICKY,” H-H Chou, 2010, BMC Bioinformatics 11:196. PMID: 20406469.

2: “Direct calibration of PICKY-designed microarrays,” H-H Chou, A. Trisiriro, S. Park, YI Hsing, PC Ronald, and PS Schnable, 2009, BMC Bioinformatics 10:347. PMID: 19849862.

3: “PICKY: oligo microarray design for large genomes”, Hui-Hsien Chou, An-Ping Hsia, Denise L. Mooney, Patrick S. Schnable, 2004, Bioinformatics 20:2893-2902. PMID: 15180932.

Intellectual Property:
Copyrighted Material - Software

 

Group:
This technology is related to ISURF 4280: High-number Gene Fragment Assembly

Stage3.png
Development Stage:
PICKY version 2.20 has been released, and Macintosh, Unix and PC versions are all available (except the Mac 64-bit version, which will be released later).  Free versions and tutorials are available for download.

Desc0000.png

]]>Wed, 13 May 2015 11:03:20 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193853554Mon, 13 Nov 2017 10:22:04 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:1: “Shared probe design and existing microarray reanalysis using PICKY,” H-H Chou, 2010, BMC Bioinformatics 11:196. PMID: 20406469.

2: “Direct calibration of PICKY-designed microarrays,” H-H Chou, A. Trisiriro, S. Park, YI Hsing, PC Ronald, and PS Schnable, 2009, BMC Bioinformatics 10:347. PMID: 19849862.

3: “PICKY: oligo microarray design for large genomes”, Hui-Hsien Chou, An-Ping Hsia, Denise L. Mooney, Patrick S. Schnable, 2004, Bioinformatics 20:2893-2902. PMID: 15180932.

]]>Intellectual Property:

]]>Group:ISURF 4280: High-number Gene Fragment Assembly

]]>Stage3.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseNon-Steroidal Anti-Inflammatory Plant Compounds for Nutraceutical or Pharmaceutical Useshttp://isurftech.technologypublisher.com/technology/19384Summary:
Iowa State University researchers have identified compounds in orangegrass that have anti-inflammatory activity.

Description:
Medicinal plants, such as St. John’s Wort, have received attention as supplements to treat various conditions or to promote general health and well-being.  These plants also represent a valuable resource for the identification of compounds that may have utility as new therapeutic agents.  Hypericum gentianoides, or orangegrass, is a plant native to the eastern half of the United States that was used by Native Americans to treat a variety of disorders, such as fever or wounds.  While investigating the properties of organgegrass, ISU researchers have identified a series of closely related compounds in its extracts that exhibit anti-inflammatory activity through inhibition of prostaglandin E synthesis.  These compounds are abundant in orangegrass relative to other secondary metabolites, demonstrate anti-inflammatory activity at low doses, and exhibit low cytotoxicity.  Thus, these natural compounds may have utility as nutraceuticals or as the basis for the design of novel therapeutic agents.

Advantage:
• Effective (doses as low as 1 ug/ml show anti-inflammatory activity)
• Abundant (the bioactive compounds account for approximately 20% of the dry plant tissue or 2% of the fresh tissue)
• Nontoxic (cytotoxicity is not observed at doses with anti-inflammatory activity)
• Versatile (may be used without modification for nutraceutical applications or as the starting point for new drug development)

Application:
Novel Anti-Inflammatory Agents for Topical Use or Drug Development

References:
“Characterizing the Metabolic Fingerprint and Anti-inflammatory Activity of Hypericum gentianoides”, Matthew L. Hillwig, Kimberly D.P. Hammer, Diane F. Birt, Eve Syrkin Wurtele, 2008, J. Agric. Food Chem., 56 (12) 4359-4366

Stage2.png
Development Stage:
Molecular structure has been identified, and anti-inflammatory activity with limited cytotoxicity has been demonstrated at concentrations as low as 2 micromolar using purified compounds in a bioassay with lipopolysaccharide-stimulated mammalian cells.  ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Wed, 13 May 2015 11:03:20 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193843460Mon, 13 Nov 2017 10:22:03 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:“Characterizing the Metabolic Fingerprint and Anti-inflammatory Activity of Hypericum gentianoides”, Matthew L. Hillwig, Kimberly D.P. Hammer, Diane F. Birt, Eve Syrkin Wurtele, 2008, J. Agric. Food Chem., 56 (12) 4359-4366

]]>Stage2.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Healthcare| Life Sciences| Veterinary MedicineAnti-Inflammatory and Anti-HIV Compositions and Methods of UseUtilityUnited States7,854,94612/129,3915/29/200812/21/20102/24/20295/13/201511/13/2017FalseDifferential ELISA for PRRSV to Distinguish Vaccinated from Infected Animalshttp://isurftech.technologypublisher.com/technology/19382Summary:
Iowa State University researchers have developed a diagnostic test that can distinguish animals vaccinated for protection against the porcine reproductive and respiratory syndrome virus (PRRSV) from those infected with the virus

Description:
PRRSV is an important pathogen of pigs, and causes hundreds of millions of dollars in losses to pork producers annually in the US alone due to reproductive disorders in sows and respiratory disease in piglets.  Modified live-attenuated vaccines (MLV and ATP) are available to help protect against PRRSV infection, but there are reports of acute PRRSV outbreaks in vaccinated herds with vaccine-like strains of the virus being identified.  This has lead to a need for a rapid assay that can be used for identifying and differentiating these vaccine-like isolates from field isolates of PRRSV.  While commercial diagnostic assays are available for PRRSV, they are unable to differentiate vaccinated animals from those that are naturally infected with the virus, or are too cumbersome and expensive for wide implementation.  To overcome these drawbacks, ISU researchers have developed an enzyme-linked immunosorbent assay (ELISA)-based diagnostic assay that distinguishes vaccinated (with MLV) from infected animals.  This assay is based upon antigenic differences in the 2b protein between the commonly used PRRSV vaccine strain and field isolates which can be used as serological markers.  The assay may thus facilitate improved management practices for pork producers.

Advantage:
Distinguishes MLV vaccinated from infected

Application:
Veterinary diagnostics

References:
“The 2b protein as a minor structural component of PRRSV”, Wai-Hong Wu, Ying Fang, Raymond R.R. Rowland, Steven R. Lawson, Jane Christopher-Hennings, Kyoung-Jin Yoon and Eric A. Nelson, 2005, Virus Res. 114:177-181.

Stage2.png
Development Stage:
An indirect ELISA has been established and shown to distinguish between the PRRSV 2b protein region from vaccine strains and other isolates, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Wed, 13 May 2015 11:03:18 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193823371Mon, 13 Nov 2017 10:22:01 GMTSummary:

]]>Description:

]]>Advantage:Distinguishes MLV vaccinated from infectedApplication:

]]>References:“The 2b protein as a minor structural component of PRRSV”, Wai-Hong Wu, Ying Fang, Raymond R.R. Rowland, Steven R. Lawson, Jane Christopher-Hennings, Kyoung-Jin Yoon and Eric A. Nelson, 2005, Virus Res. 114:177-181.

]]>Stage2.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Differential Immunoassay for PRRS Vaccine AntibodyContinuationUnited States8,541,18813/298,77611/17/20119/24/20139/25/20275/13/201511/13/2017FalseUniversal and Differential Serologic Assay for Influenza A Virushttp://isurftech.technologypublisher.com/technology/19381Summary:
ISU researchers have developed a diagnostic assay for swine influenza (Influenza A) that can distinguish between exposed and vaccinated animals. This ELISA-based assay is also able to detect all Influenza A viruses, regardless of subtype. The assay represents an improvement over currently available tests, and may help pork producers in managing this costly disease.

Description:
Swine influenza, or Influenza A, is an acute respiratory disease that can affect pigs of all ages and results in significant economic losses for pork producers. While detection of swine influenza virus (SIV) or viral antigen in the lung or nasal secretions from symptomatic animals is considered the definitive diagnosis of swine influenza, serologic tests are often used to detect animals that have been exposed to the virus since the disease has a very short duration and the virus quickly becomes undetectable. However, interpretation of serologic test results for the diagnosis of SIV is made difficult by the intensive use of vaccination, and the emergence of new subtypes and antigenic drift within a subtype. To address the need for serologic assays for SIV that detect infection regardless of subtype or antigenic variation, as well as the need to differentiate exposed from vaccinated animals, ISU researchers have developed a universal and differential serologic assay for influenza A virus. This ELISA-based assay detects two antigens: one that is conserved among all influenza A viruses, and a second antigen that is expressed in exposed but not vaccinated pigs.

Advantage:
• Comprehensive (the assay detects an antigen conserved among all swine influenza virus subtypes)
• Differential (can distinguish between exposed and vaccinated animals)
• Stable (use of recombinant antigens enables continuous production of reagents)

Application:
Diagnosis of swine influenza (Influenza A)

References:
“Characterization of the humoral immune response of experimentally infected and vaccinated pigs to swine influenza viral proteins”, Won-Il Kim, Wai-Hong Wu, Bruce Janke, and Kyoung-Jin Yoon, 2005, Arch. Viol. DOI: 10.1007/s00705-005-0615-9.

Stage2.png
Development Stage:
The serologic assay has been used to characterize the antibody responses of pigs to SIV antigens, and is ready for additional field evaluation.

Desc0000.png

]]>Wed, 13 May 2015 11:03:16 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193813288Mon, 13 Nov 2017 10:21:59 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:“Characterization of the humoral immune response of experimentally infected and vaccinated pigs to swine influenza viral proteins”, Won-Il Kim, Wai-Hong Wu, Bruce Janke, and Kyoung-Jin Yoon, 2005, Arch. Viol. DOI: 10.1007/s00705-005-0615-9.

]]>Stage2.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineUniversal and Differential Serologic Assay for Swine Influenza VirusUtilityUnited States7,892,72911/473,4346/23/20062/22/20116/15/20285/13/201511/13/2017FalseSingle Dose Controlled Release Vaccine Formulations Using Polyanhydride Microsphereshttp://isurftech.technologypublisher.com/technology/19380Summary:
Iowa State University researchers have developed controlled release vaccine formulations that may have utility for inducing certain types of immune responses

Description:
Successful vaccination often requires multiple immunization shots or boosters to offer complete protection.  In addition, generation of the appropriate type of immune response is also critical for developing immunity, and may be dependent on the type of adjuvant used in the vaccine preparation.  ISU researchers have developed a single-dose, controlled release vaccine formulation based on polyanhydride microspheres.  The microspheres can be loaded with antigenic proteins for immunization, and the microsphere composition controls the release of the antigen.  The need for alum-based adjuvants that tend to induce Th2 immunity is obviated. Additionally, preferential Th1 versus Th2 immune responses can be induced based on how the microspheres are loaded with antigen.  This type of vaccination strategy may improve protection against intracellular pathogens, and be especially useful for the development of vaccines against certain cancers and viruses.  These single dose controlled release vaccine formulations have the potential to simplify vaccination schedules and facilitate mass immunization campaigns. 

Advantage:
• Single-dose vaccine formulation that can be modulated to induce Th1 versus Th2 cellular immunity.
• Reduces the need for adjuvants and may improve safety.
• May replace multiple injections required for some conventional vaccines, resulting in greater compliance with recommended immunization schedules

Application:
Production of single-dose vaccines for certain cancers, viruses and intracellular pathogens; especially useful for the induction of Th1 immune response.

References:
1: “Encapsulation, stabilization, and release of BSA-FITC from polyanhydride microspheres”, Amy S. Determan, Brian G. Trewyn, Victor S.-Y. Lin, Marit Nilsen-Hamilton, and Balaji Narasimhan, 2004, J. Controlled Release 100:97-109.

2: “Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism”, Matt J. Kipper, Jennifer H. Wilson, Michael J. Wannemuehler , Balaji Narasimhan, 2006, J. Biomed. Materials. Res. 76:798-810.

3: “Single-dose vaccine carrier for modulation of immune response mechanisms”, Matt J. Kipper, Jennifer Wilson, Michael Wannemuehler, and Balaji Narasimhan, 2004, AIChE Annual Meeting, Austin, TX.

This technology is related to ISURF #4211: Polyanhydride Nanoparticles for Enhanced Delivery of Antiparasites and ISURF #3729: A Drug Delivery Platform for Targeting Intracellular Pathogens

Stage2.png
Development Stage:
Induction of Th1 immunity has been demonstrated following intramuscular injection using the vaccine formulation loaded with tetanus toxoid.

Desc0000.png

]]>Wed, 13 May 2015 11:03:15 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193803176Mon, 13 Nov 2017 10:21:58 GMTSummary:

]]>Description:ISU researchers have developed a single-dose, controlled release vaccine formulation based on polyanhydride microspheres.  The microspheres can be loaded with antigenic proteins for immunization, and the microsphere composition controls the release of the antigen.  The need for alum-based adjuvants that tend to induce Th2 immunity is obviated. Additionally, preferential Th1 versus Th2 immune responses can be induced based on how the microspheres are loaded with antigen.  This type of vaccination strategy may improve protection against intracellular pathogens, and be especially useful for the development of vaccines against certain cancers and viruses.  These single dose controlled release vaccine formulations have the potential to simplify vaccination schedules and facilitate mass immunization campaigns. 

]]>Advantage:Application:

]]>References:1: “Encapsulation, stabilization, and release of BSA-FITC from polyanhydride microspheres”, Amy S. Determan, Brian G. Trewyn, Victor S.-Y. Lin, Marit Nilsen-Hamilton, and Balaji Narasimhan, 2004, J. Controlled Release 100:97-109.

2: “Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism”, Matt J. Kipper, Jennifer H. Wilson, Michael J. Wannemuehler , Balaji Narasimhan, 2006, J. Biomed. Materials. Res. 76:798-810.

3: “Single-dose vaccine carrier for modulation of immune response mechanisms”, Matt J. Kipper, Jennifer Wilson, Michael Wannemuehler, and Balaji Narasimhan, 2004, AIChE Annual Meeting, Austin, TX.

]]>ISURF #4211: Polyanhydride Nanoparticles for Enhanced Delivery of Antiparasites and ISURF #3729: A Drug Delivery Platform for Targeting Intracellular Pathogens

]]>Stage2.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life Sciences| Veterinary MedicineControlled-Release Immunogenic Formulations to Modulate Immune ResponseUtilityUnited States7,858,09311/262,31010/28/200512/28/201010/28/20255/13/201511/13/2017Controlled-Release Immunogenic Formulations to Modulate Immune ResponseContinuationUnited States8,173,10412/554,2829/4/20095/8/20126/9/20255/13/201511/13/2017FalseSoybean Transformation and Regeneration Using Half-Seed Explantshttp://isurftech.technologypublisher.com/technology/19379Summary:
Iowa State University researchers have developed a more efficient and robust method for genetic transformation and regeneration of soybeans using half-seed explants of mature soybean seeds.

Description:
Commonly used methods for soybean transformation such as the cotyledonary node (“coty node”) or embryogenic callus (“callus”) method have various disadvantages.  For example, the coty node method requires precise wounding of seedlings to introduce genetic material and in vitro germination that can result in low transformation efficiencies, poor reproducibility and non-germline transformation.  The callus method—in which embryonic tissue is bombarded with DNA-coated carrier particles—has the drawbacks of requiring a prolonged tissue culture period, and can also result in the complex insertion of genes into the plant genome and may result in the regeneration of sterile plants.  To overcome these disadvantages, ISU researchers have developed a method for efficient soybean transformation and regeneration using half-seed explants.  In this method, half-seed explants (separated cotyledonous tissues derived from mature soybeans) are infected with Agrobacterium tumefaciens carrying a transgene of interest and regenerated in vitro using tissue culture medium.  Transgenic plants can be obtained within 9-10 months, and any suitable genotype of soybean can be used with this method.  Because this approach does not require technical precision or prolonged tissue culture, it is more efficient and robust than other soybean transformation methods.

Advantage:
• Efficient (transformation efficiency of 2.4 - 7.8% compared to 0.3 – 2.8% for the coty node method has been demonstrated) 
• Simple (the half-seed method is easy to prepare and does not require a prolonged tissue culture period when compared to the callus culture system)
• Reproducible (does not require precise wounding or particle bombardment, so gene insertion events and transformation are more reliable)

Application:
Soybean transformation

References:
“Improved cotyledonary node method using an alternative explant derived from mature seed for efficient Agrobacterium-mediated soybean transformation”, M. Paz, J.C. Martinez, A. Kalvig, T. Fonger, and K. Wang, 2006, Plant Cell Reports 25: 206-213.

Supporting Documents:


MS PowerPoint:  Soybean Transformation and Regeneration Using “Half-Seed” Explants

Stage5.png
Development Stage:
Transgenic soybean plants derived from the half-seed explants have been produced and confirmed in the R0 and R1 generations through molecular analysis, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Wed, 13 May 2015 11:03:14 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193793122Mon, 13 Nov 2017 10:21:57 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:“Improved cotyledonary node method using an alternative explant derived from mature seed for efficient Agrobacterium-mediated soybean transformation”, M. Paz, J.C. Martinez, A. Kalvig, T. Fonger, and K. Wang, 2006, Plant Cell Reports 25: 206-213.

]]>

]]>Soybean Transformation and Regeneration Using “Half-Seed” Explants

]]>Stage5.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Soybean Transformation and Regeneration Using Half-Seed ExplantUtilityUnited States7,473,82211/475,3186/27/20061/6/20098/7/20275/13/201511/13/2017FalseA Drug Delivery Platform for Targeting Intracellular Pathogenshttp://isurftech.technologypublisher.com/technology/19374Summary:
Iowa State University researchers have developed an improved method for delivering antibiotics inside infected cells for more effective treatment.

Description:
Bioerodible polymers have been researched for potential biomedical applications like drug or vaccine delivery for a number of years.  For example, polyesters such as poly(lactic-co-glycolic acid) (PLGA) have been FDA approved for some applications; however, their suitability for others, such as vaccine delivery, is limited by factors that affect the stability of protein immunogens, such as producing a low pH milieu or inducing protein aggregation as well as acidic compartmentalization that is detrimental to the effectiveness of most antibiotics. In contrast, polyanhydrides have a number of potential advantages for biomedical applications, including chemistry-dependent surface erosion and payload release, a moderate pH microenvironment, and better protein stabilization; polyanhydrides have been used for delivery of plasmid DNA, small molecular weight compounds, and vaccine components.  In addition, polyanhdride microspheres and nanospheres (PAparticles) elicit unique cellular responses from immune cells that stimulate internalization, direct intracellular trafficking and degrade slowly within the cells.  Varying the chemistry of the particle affects particle degradation and alters the fate of the particle within cells. This characteristic can be exploited to target intracellular pathogens which evade host defenses by adapting themselves to the environment within cells and escape killing by antibiotics.  ISU researchers have now developed PAparticles with modified surface chemistries that are capable of entering host cells and delivering antibiotics in the same microenvironment as that of an intracellular pathogen.  Loading of the antibiotics onto the PAparticles does not chemically modify the antibiotics or negate their antimicrobial function. This highly effective targeting of the intracellular environment has to potential to reduce the amount of antibiotic needed to treat such an infection and also provide delayed release, thus improving the bioavailablity of the drug.

Advantage:
• Enhanced uptake compared to PLGA particles
• Targets more favorable intracellular compartments
• Potential for longer bioavailability of encapsulated antibiotics
• Provides greater encapsulation of hydrophobic antibiotics compared to PLGA particles

Application:
Drug delivery

References:
1: “Polymer Chemistry Influences Monocytic Uptake of Polyanhydride nanospheres” B. Ulery, Y. Phanse, A. Sinha, M. Wannemuehler, B. Narasimhan, and B. Bellaire, 2009, Pharm. Res. 26:683-690.

Group:
This technology is related to ISURF #4211: Polyanhydride Nanoparticles for Enhanced Delivery of Antiparasites and ISURF #3176: Single Dose Controlled Release Vaccine Formulations Using Polyanhydride Microspheres

Stage0.png
Development Stage:
Co-localization of the polyanhydride particles with the intracellular pathogen M. paratuberculosis in tissue culture cells has been demonstrated, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Wed, 13 May 2015 11:03:10 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193743729Mon, 13 Nov 2017 10:21:55 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:1: “Polymer Chemistry Influences Monocytic Uptake of Polyanhydride nanospheres” B. Ulery, Y. Phanse, A. Sinha, M. Wannemuehler, B. Narasimhan, and B. Bellaire, 2009, Pharm. Res. 26:683-690.

]]>Group:ISURF #4211: Polyanhydride Nanoparticles for Enhanced Delivery of Antiparasites and ISURF #3176: Single Dose Controlled Release Vaccine Formulations Using Polyanhydride Microspheres

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Healthcare| Life Sciences| Veterinary MedicineAntimicrobial Compositions and MethodsUtilityUnited States8,449,91612/940,87211/5/20105/28/20134/10/20315/13/201511/13/2017Antimicrobial Polyanhydride NanoparticlesContinuationUnited States8,927,02413/866,5204/19/20131/6/201511/5/20305/13/201511/13/2017FalseGenes Controlling Plant Growthhttp://isurftech.technologypublisher.com/technology/19373Summary:
Iowa State University researchers have identified a gene, termed HERK1, which increases plant growth in a model system when it is overexpressed. 

Description:
A variety of internal (e.g., hormones) and external signals (e.g., light) are known to play a role in the regulation of plant growth. These regulatory pathways are complex and can intersect at a variety of levels; for example, brassinosteroids (BRs), a group of plant steroid hormones, controls cell elongation in plants in conjunction with environmental cues. As part of a research effort to probe the intricate mechanisms involved in regulating plant growth, ISU researchers have discovered that a family of receptor-like kinases, including HERCULES1, THESEUS1, and FERONIA, are regulated by BRs and are required for optimal plant growth. Studies by the ISU group have shown that this previously unknown pathway plays a role in cell elongation, with overexpression of HERK1 resulting in increasing a plant’s size by 10-15% using an Arabidopsis model, while underexpression of HERK1 and related genes resulted in plants that were approximately 50% smaller. Additional research into pathway this may result in strategies for increasing the size and yield of grain and biomass crops. 

Advantage:
• Shown experimentally to increase plant growth 10-15%
• <May improve grain and biomass yields/rss.Adv2>

Application:
Control of plant growth.

References:
1: “Three related receptor-like kinases are required for optimal cell elongation in Arabidopsis thaliana”, H. Guo, L. Li, H. Ye, X. Yu, A. Algreen, and Y. Yin, Y.,  2009, Proc Natl Acad Sci USA 106:7648-7653.

2: “A Family of Receptor-Like Kinases Are Regulated by BES1 and Involved in Plant Growth in Arabidopsis thaliana”, H. Guo, H. Ye, L. Li, L., and Y. Yin, 2009, Plant Signaling & Behavior 4:784-786.

Stage0.png
Development Stage:
Overexpression of the HERK1 receptor kinase has been demonstrated to increase plant growth using an Arabidopsis thaliana model system, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Wed, 13 May 2015 11:03:09 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193733723Mon, 13 Nov 2017 10:21:54 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:1: “Three related receptor-like kinases are required for optimal cell elongation in Arabidopsis thaliana”, H. Guo, L. Li, H. Ye, X. Yu, A. Algreen, and Y. Yin, Y.,  2009, Proc Natl Acad Sci USA 106:7648-7653.

2: “A Family of Receptor-Like Kinases Are Regulated by BES1 and Involved in Plant Growth in Arabidopsis thaliana”, H. Guo, H. Ye, L. Li, L., and Y. Yin, 2009, Plant Signaling & Behavior 4:784-786.

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesModulation of receptor-Like Kinases for Promotion of Plant GrowthContinuationUnited States9,512,44013/773,1502/21/201312/6/20161/31/203312/15/201611/13/2017FalseEnhanced Plant Growth through Mobile RNA Signalshttp://isurftech.technologypublisher.com/technology/19371Summary:
Iowa State University researchers have identified mobile RNAs in potatoes whose overexpression enhances plant growth.

Description:
Plants have evolved intricate signaling pathways to regulate growth and other physiological processes. Light quality and duration play an important role in providing external cues perceived by the plant. Photoperiod is an example of one such external signal that controls important physiological processes like flowering, dormancy, germination, senescence, and tuber formation. During tuber formation, a graft-transmissible signal initiated in the leaves moves through the vascular system to induce a growth response.  ISU researchers have discovered that this signal is due to mobile RNAs encoding for two transcription factors (BEL and KNOX) and shown that their overexpression enhances plant growth even under non-inductive conditions.   In addition to a substantial increase in the number of tubers and the potential to regulate flowering, this technology may have utility for acceleration of tuber growth in field plants, thus shortening the time for field cultivation.  It could also be used to shorten the timing of a “late” potato variety to produce an earlier harvest.  This technology may also have utility for the production of bio-pharmaceuticals or other useful compounds in potatoes.

Advantage:
• Acceleration of  tuber growth, shortening the time for field cultivation
• Potential for earlier harvest for “late” potato varieties
• May be used to regulate flowering
• Enhanced tuber formation

Application:
Plant production

References:
1: “Interacting Transcription Factors from the Three-Amino Acid Loop Extension Superclass Regulate Tuber Formation,” Chen, H., Rosin, F.M., Prat, S., and Hannapel, D. J., 2003, Plant Physiol. 132:1391-1404.

 

Group:
This technology is related to ISURF 4587: Potato tuber yield enhancement

 

Stage0.png
Development Stage:
Transgenic lines of potatoes have been shown to produce more tubers at a faster rate than controls, and ISU is seeking partners interested in commercializing this technology.

Desc0000.png

]]>Wed, 13 May 2015 11:03:08 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/193713056Mon, 13 Nov 2017 10:21:53 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:1: “Interacting Transcription Factors from the Three-Amino Acid Loop Extension Superclass Regulate Tuber Formation,” Chen, H., Rosin, F.M., Prat, S., and Hannapel, D. J., 2003, Plant Physiol. 132:1391-1404.

]]>Group:ISURF 4587: Potato tuber yield enhancement

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesMobile RNA Acts as a Signal to Regulate Plant Growth and DevelopmentUtilityUnited States7,579,15011/172,0236/30/20058/25/20093/26/20275/13/201511/13/2017FalseTrees for Woody Biomass Applications: Improved Aspen Cloneshttp://isurftech.technologypublisher.com/technology/19682

Summary:
Improved aspen clones that produce increased biomass have been developed at Iowa State University.

Description:
Fast growing trees such as aspen, cottonwood, and eucalyptus can be grown as so-called short rotation crops, and have potential to be used as a source of woody biomass for the production of biofuels such as wood pellets and cellulosic ethanol.  In the prime cottonwood growing region, which includes eastern Louisiana, eastern Arkansas, western Mississippi and western Kentucky, cottonwoods can grow 12-15 feet per year, allowing them to be harvested biennially.   In addition, cottonwoods will regrow from stumps, so that plantings may be managed through coppicing. However, cottonwoods in the Great Plains are susceptible to melampsora leaf rust, which reduces their vigor.  Aspens are also being targeted for development as a bioenenergy crop with the added advantage that they re-sprout from both the stumps and the roots.  Improved hybrid aspen clones that produce increased biomass have been developed at Iowa State University.  These trees may facilitate the development of aspen plantations for biomass production in Iowa and similar climatic zones.

Advantage:
• The non-GMO hybrid aspen clones have increased biomass production, good ability to re-sprout, and have the potential to be grown on marginal lands

Application:
Bioenergy; paper and pulp

References:
Headlee, W. L. et al. 2013. Establishment of alleycropped hybrid aspen “Crandon” in Central Iowa: effects of topographic position and fertilizer rate on above ground biomass production and allocation.  Sustainability 5:2874-2886

Group:
This technology is related to ISURF #4156: Trees for Woody Biomass Applications: Improved Cottonwoods

Intellectual Property:
Tangible Material

Stage4.png
Development Stage:
The trees have been growing for several years and could be propagated by shoot or root cuttings

Desc0000.png

]]>Mon, 01 Jun 2015 11:49:53 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/196824157Mon, 13 Nov 2017 10:21:36 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:Headlee, W. L. et al. 2013. Establishment of alleycropped hybrid aspen “Crandon” in Central Iowa: effects of topographic position and fertilizer rate on above ground biomass production and allocation.  Sustainability 5:2874-2886

]]>Group:ISURF #4156: Trees for Woody Biomass Applications: Improved Cottonwoods

]]>Intellectual Property:

]]>Stage4.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalsePorcine Rotavirus Isolates for Improved Vaccines: Group Ahttp://isurftech.technologypublisher.com/technology/19286Summary:
Iowa State University researchers have isolated porcine rotaviruses from Groups A and C that may have utility for improved vaccines and diagnostics.

Description:
Porcine rotavirus is very widespread in pig populations, and young animals are particularly susceptible to infection.  Porcine rotavirus also causes significant economic losses to pork producers due to mortality and lost productivity.  Rotavirus persists in the environment and resists disinfectants, so management practices are an important part of preventing and controlling infection.  There are a wide variety of different porcine rotavirus strains, with Group A rotaviruses of G9 genotype representing the majority of contemporary group A porcine rotaviruses causing enteric disease in weaned piglets in the US and elsewhere, and group C rotavirus G6 isolates representing a majority of contemporary type C rotaviruses causing severe diarrhea in neonates.  A licensed commercial vaccine is available to help combat infection by porcine rotavirus, but it contains only group A viruses which belong to G4 and G5 types; no vaccine against Group C rotavirus is apparently currently available, so vaccinated pigs or piglets may still be vulnerable to infection.  To address this challenge, ISU researchers have recently isolated, characterized, and reliably propagated a Group A rotaviruses of G9 genotype as well as a group C porcine rotavirus G6 from infected piglets showing clinical symptoms. In addition to their utility as reference strains, these rotavirus isolates may also be used for the development of improved vaccines against porcine rotavirus as well as for the production of diagnostic reagents or kits.

Advantage:
• Can be reliably propagated in an in vitro system
• Pure isolate
• Replicates to relatively high titer

Application:
Veterinary vaccines and diagnostics; reference strain

Intellectual Property:
Tangible Material

Group:
This technology is related to ISURF #3935: Porcine Rotavirus Isolates for Improved Vaccines: Group C

Stage0.png
Development Stage:
The Group A and Group C porcine rotavirus isolates have been adapted to an in vitro cell culture system, their pathogenicity has been assessed, and they have been demonstrated to be free of any other contaminants.  ISU is seeking partners interested in commercializing these isolates for vaccine or diagnostics development.

Desc0000.png

]]>Fri, 08 May 2015 09:01:43 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/192863936Mon, 13 Nov 2017 10:21:35 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>Intellectual Property:

]]>Group:ISURF #3935: Porcine Rotavirus Isolates for Improved Vaccines: Group C

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseSMN2 Catalytic Core: A Novel Approach for Spinal Muscular Atrophy Treatmenthttp://isurftech.technologypublisher.com/technology/19204Summary:
Iowa State University researchers have identified a new approach for the development of treatments for spinal muscular atrophy using an antisense oligonucleotide.

Description:
Spinal muscular atrophy (SMA) is a neurodegenerative disorder that affects the control of muscle movement and is a leading genetic cause of infant mortality.  SMA is divided into four subtypes based on disease severity and the age at which it manifests. In humans, there are two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2.  Loss of SMN1 in conjunction with skipping of SMN2 exon 7 in pre-mRNA splicing—which results in a truncated, unstable SMN—leads to SMA.  Strategies to correct the splicing aberration in SMN2 are believed to hold promise for a cure for SMA, and have included screening many small compounds as well as the use of short antisense oligonucleotides (ASO).  To date, however, no small compounds or ASO have been identified that can correct the SMN2 splicing defect.  As part of an ongoing research program in SMA, ISU researchers have now identified a novel short antisense oligonucleotide that corrects the aberrant splicing in SMN2.  This ASO may have utility as a potential treatment for SMA since it offers low cost synthesis, high target specificity, ease of manipulation and potential to cross the blood brain barrier.

Advantage:
• Low cost of synthesis due to small size
• High target specificity and low off-target effect
• Effective at very low dose
• Amenable to modifications for transport across blood brain barrier
• Unique mechanism of splicing regulation through modulation of catalytic core of spliceosome

Application:
Development of drugs for the treatment of spinal muscular atrophy

References:
1: A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. Singh N.N., Shishimorova M., Cao L.C., Gangwani L., Singh R.N. 2009.  RNA Biol. 6:341-50.

2: Antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing”, Singh, N.N., Hollinger K., Bhattacharya, D. and Singh, R.N. 2010. RNA 16:1167-1181.

3: Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model. Singh N.N., Singh R.N. 2011. RNA Biol. 8(4). Epub ahead of print June 9, 2011.

Stage0.png

Desc0000.png

]]>Tue, 05 May 2015 10:39:06 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/192043810Mon, 13 Nov 2017 10:21:15 GMTSummary:

]]>Description:Survival Motor Neuron (SMN) gene, SMN1 and SMN2.  Loss of SMN1 in conjunction with skipping of SMN2 exon 7 in pre-mRNA splicing—which results in a truncated, unstable SMN—leads to SMA.  Strategies to correct the splicing aberration in SMN2 are believed to hold promise for a cure for SMA, and have included screening many small compounds as well as the use of short antisense oligonucleotides (ASO).  To date, however, no small compounds or ASO have been identified that can correct the SMN2 splicing defect.  As part of an ongoing research program in SMA, ISU researchers have now identified a novel short antisense oligonucleotide that corrects the aberrant splicing in SMN2.  This ASO may have utility as a potential treatment for SMA since it offers low cost synthesis, high target specificity, ease of manipulation and potential to cross the blood brain barrier.

]]>Advantage:]]>Application:

]]>References:1: A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. Singh N.N., Shishimorova M., Cao L.C., Gangwani L., Singh R.N. 2009.  RNA Biol. 6:341-50.

2: Antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing”, Singh, N.N., Hollinger K., Bhattacharya, D. and Singh, R.N. 2010. RNA 16:1167-1181.

3: Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model. Singh N.N., Singh R.N. 2011. RNA Biol. 8(4). Epub ahead of print June 9, 2011.

]]>Stage0.pngDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Healthcare| Life SciencesSpinal Muscular Atrophy Treatment via Targeting SMN2 Catalytic CoreUtilityUnited States8,802,64213/093,9584/26/20118/12/20147/17/20315/5/201511/20/2017Spinal Muscular Atrophy Treatment via Targeting SMN2 Catalytic CoreContinuationUnited States9,217,14714/134,05712/19/201312/22/20154/30/203112/23/201511/13/2017FalsePorcine Rotavirus Isolates for Improved Vaccines: Group Chttp://isurftech.technologypublisher.com/technology/19285Summary:
Iowa State University researchers have isolated porcine rotaviruses from Groups A and C that may have utility for improved vaccines and diagnostics.

Description:
Porcine rotavirus is very widespread in pig populations, and young animals are particularly susceptible to infection.  Porcine rotavirus also causes significant economic losses to pork producers due to mortality and lost productivity.  Rotavirus persists in the environment and resists disinfectants, so management practices are an important part of preventing and controlling infection.  There are a wide variety of different porcine rotavirus strains, with Group A rotaviruses of G9 genotype representing the majority of contemporary group A porcine rotaviruses causing enteric disease in weaned piglets in the US and elsewhere, and group C rotavirus G6 isolates representing a majority of contemporary type C rotaviruses causing severe diarrhea in neonates.  A licensed commercial vaccine is available to help combat infection by porcine rotavirus, but it contains only group A viruses which belong to G4 and G5 types; no vaccine against Group C rotavirus is apparently currently available, so vaccinated pigs or piglets may still be vulnerable to infection.  To address this challenge, ISU researchers have recently isolated, characterized, and reliably propagated a Group A rotaviruses of G9 genotype as well as a group C porcine rotavirus G6 from infected piglets showing clinical symptoms. In addition to their utility as reference strains, these rotavirus isolates may also be used for the development of improved vaccines against porcine rotavirus as well as for the production of diagnostic reagents or kits.

Advantage:
• Can be reliably propagated in an in vitro system
• Pure isolate
• Replicates to relatively high titer

Application:
Veterinary vaccines and diagnostics; reference strain

Intellectual Property:
Tangible Material

Group:
This technology is related to ISURF #3936: Porcine Rotavirus Isolates for Improved Vaccines: Group A

Stage0.png
Development Stage:
The Group A and Group C porcine rotavirus isolates have been adapted to an in vitro cell culture system, their pathogenicity has been assessed, and they have been demonstrated to be free of any other contaminants.  ISU is seeking partners interested in commercializing these isolates for vaccine or diagnostics development.

Desc0000.png

]]>Fri, 08 May 2015 09:01:43 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/192853935Mon, 13 Nov 2017 10:21:14 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>Intellectual Property:

]]>Group:ISURF #3936: Porcine Rotavirus Isolates for Improved Vaccines: Group A

]]>Stage0.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseDisease Resistant Ricehttp://isurftech.technologypublisher.com/technology/19134Summary:
Iowa State University researchers have developed disease resistant rice using genome editing technology.

Description:
Bacterial blight is a major disease in rice—a crop that feeds half the world’s population. The TALEs (transcription activator-like effectors) proteins secreted by Xanthomonas bacteria  induce disease in susceptible rice plants  by binding to specific DNA sequences to activate gene expression. In rice, TALEs  secreted by X. oryzae pv. oryzae (Xoo) act as virulence factors and activate transcription of disease susceptibility, or S genes. One important bacterial blight susceptibility gene is Os11N3.To test the possibility of developing bacterial blight resistant plants, ISU researchers used the targeted genome editing capability of TALENs (TAL effectors fused to a DNA cleavage domain to generate specific nucleases) to edit the Os11N3 gene. The experiments were successful resulting in disease resistant mutant plants that were morphologically normal compared to wild-type plants, indicating that the known developmental function of Os11N3 was preserved.  This application demonstrates the utility of TALENs for making specific modifications in endogenous plant genes, and consequently may have broad applicability for streamlining plant breeding for the development of new agronomically important traits.

Advantage:
• Increased bacterial blight resistance without introducing foreign genes
• Rapid route to creating disease-resistant rice in elite lines

Application:
Crop improvement

References:
1: “High-efficiency TALEN-based gene editing produces disease-resistant rice”, T. Li., B. Liu., M. Spalding, D. Weeks, and B. Yang. 2012. Nature Biotechnology 30:390-392.

Development Stage:
Stage2.png

Desc0000.png

]]>Mon, 04 May 2015 07:01:20 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/191343974Mon, 13 Nov 2017 10:21:00 GMTSummary:

]]>Description:

]]>Advantage:]]>]]>Application:

]]>References:1: “High-efficiency TALEN-based gene editing produces disease-resistant rice”, T. Li., B. Liu., M. Spalding, D. Weeks, and B. Yang. 2012. Nature Biotechnology 30:390-392.

]]>Development Stage:Stage2.pngDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesGenetically Modified Plants with Resistance to Xanthomonas and Other Bacterial Plant PathogensUtilityUnited States9,688,99714/362,5296/3/20146/27/20178/16/20347/17/201711/13/2017FalseContemporary Bovine Viral Diarrhea (BVD) Viruses for Improved Vaccineshttp://isurftech.technologypublisher.com/technology/19132Summary:
An Iowa State University researcher has purified a set of contemporary bovine viral diarrhea virus isolates that may be useful as vaccine strains.

Description:
The bovine viral diarrhea virus (BVDV) causes disease in cattle and other ruminants. Diseased animals may show respiratory and reproductive symptoms ranging from mild to very severe, in some cases resulting in the death of the animal. The disease primarily affects young cattle and usually results in mucosal lesions that can be misdiagnosed because of their similarity to infections by other viruses. BVDV effects significant economic losses to producers globally, and persistently infected cattle may explain the magnitude of such loses since the persistently infected animals are disease reservoirs. Treatment is usually supportive therapy, while control is through management practices (e.g., good biosecurity), elimination of infected animals, and vaccination. While there are a number of BVDV vaccines available, vaccination programs do not provide complete herd protection, which is likely due to an incomplete correspondence between the contemporary antigenic determinants in the field compared to those used for vaccination.  For example, most commercially available modified live vaccines do not appear to protect against BVDV-1b, a strain that emerged in the 1990s in persistently infected cattle.  An ISU investigator has isolated contemporary BVDVs comprising various genotypes (e.g., type 1a, 1b or 2) and biotypes (cytopathic or non-cytopathic strains). Some of the ISU isolates came from diseased animals vaccinated with commercially available BVDV vaccines, further suggesting that current vaccines need to be updated.  Consequently, these new isolates may be useful to develop improved vaccines. Other uses include diagnostics and as challenge strains for vaccine development.

Advantage:
• More representative of currently circulating BVDV strains than strains used in current commercial vaccines
• Include various genotypes and biotypes
• Have utility for vaccine development, diagnostics, or as challenge strains

Application:
Animal health

Intellectual Property:
Tangible Material

Development Stage:
Stage1.png
Fourteen BVD V isolates representing different geographic origins (IA, MO, TN) and comprising various genotypes and biotypes have been purified, and ISU is seeking commercialization partners.

Desc0000.png

]]>Mon, 04 May 2015 07:01:18 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/191324007Mon, 13 Nov 2017 10:20:58 GMTSummary:

]]>Description:

]]>Advantage:]]>Application:

]]>Intellectual Property:

]]>Development Stage:Stage1.png

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineFalseMycoplasma hyorhinis Field Isolates for Vaccine Developmenthttp://isurftech.technologypublisher.com/technology/19127Summary:
An Iowa State University researcher has cultured clinical isolates of Mycoplasma hyorhinis that may have utility for vaccine development.

Description:
Mycoplasma hyorhinis has historically been considered to be a normal comensal organism found in the respiratory tracts of pigs.  More recently, however, M. hyorhinis has been found to be a primary cause of polyserositis in pigs, and has been found also found in association with other important pig pathogens, such as M. hyopneumoniae, the principal causative agent of enzootic pneumonia, and viruses such as porcine respiratory and reproductive syndrome virus (PRRSV).  M. hyorhinis has also been found to cause arthritis in pigs.  Commercial vaccines for protection against M. hyorhinis infection are not available at present, and a limited number of isolates are available for vaccine development since only a few laboratories have M. hyorhinis diagnostic and culturing capabilities.  As part of investigations in M. hyorhinis diagnostics, an ISU researcher has cultured clinical isolates of this organism.  This series of field isolates may be useful for the development of vaccines to protect against M. hyorhinis infection, as well as for serving as challenge strains to determine vaccine efficacy.

Advantage:
• Increases number of isolates available for vaccine development

Application:
Vaccine development; challenge strains

Intellectual Property:
Tangible Material

Development Stage:
Stage1.png

Desc0000.png

]]>Mon, 04 May 2015 07:01:15 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/191274053Mon, 13 Nov 2017 10:20:55 GMTSummary:

]]>Description:Mycoplasma hyorhinis has historically been considered to be a normal comensal organism found in the respiratory tracts of pigs.  More recently, however, M. hyorhinis has been found to be a primary cause of polyserositis in pigs, and has been found also found in association with other important pig pathogens, such as M. hyopneumoniae, the principal causative agent of enzootic pneumonia, and viruses such as porcine respiratory and reproductive syndrome virus (PRRSV).  M. hyorhinis has also been found to cause arthritis in pigs.  Commercial vaccines for protection against M. hyorhinis infection are not available at present, and a limited number of isolates are available for vaccine development since only a few laboratories have M. hyorhinis diagnostic and culturing capabilities.  As part of investigations in M. hyorhinis diagnostics, an ISU researcher has cultured clinical isolates of this organism.  This series of field isolates may be useful for the development of vaccines to protect against M. hyorhinis infection, as well as for serving as challenge strains to determine vaccine efficacy.

]]>Advantage:Application:

]]>Intellectual Property:

]]>Development Stage:Stage1.pngDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Life Sciences| Veterinary MedicineFalseMidwest Adapted Haploid Inducer for Maizehttp://isurftech.technologypublisher.com/technology/19126Summary:
Iowa State University researchers have developed a new haploid inducer for maize that is adapted to growing conditions in the Midwest.

Description:
Inbred corn lines have two identical copies of their genome, and are valuable breeding resources since offspring are identical to their parent. Since offspring of hybrids are genetically segregating, hybrid seed needs to be generated from genetically stable, parental inbred lines. Development of traditional corn inbred lines starts from heterozygous plants and requires continued self-pollination, which takes five to eight generations before an inbred line is pure enough to be combined with another inbred line to create a hybrid. Doubled haploid (DH) technology can be used to produce pure, inbred corn lines in just two generations, since the initial “haploid” offspring contain only a single genome instead of two, which is then doubled in this DH procedure.  So-called inducer lines are used as pollinators in the DH approach.  However, inducer lines currently available for licensing are European in origin and are poorly adapted to growing conditions found in the US Corn Belt in the Midwest in that they can have poor germination rates, can be susceptible to wind (lodging), have poor seed set and are susceptible to mold.  To overcome the limitations of currently available inducer lines, ISU researchers have developed a haploid inducer for maize that is better adapted to the conditions found during a typical growing season in the Midwest. Midwest adapted inducers can benefit corn breeding companies, but may be particularly attractive to smaller companies in the US and abroad.

Advantage:
• Better suited for Midwest corn growing season
• Haploid induction rates comparable to European inducers
• Simple phenotypic seed color selection

Application:
Plant breeding

Intellectual Property:
Tangible Material

Group:
This technology is related to ISURF #4099: Haploid Inducing Genotype for Field and Specialty Corn

Development Stage:
Stage4.png
Ready for release.

Desc0000.png

]]>Mon, 04 May 2015 07:01:15 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/191264065Mon, 13 Nov 2017 10:20:54 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>Intellectual Property:

]]>Group:ISURF #4099: Haploid Inducing Genotype for Field and Specialty Corn

]]>Development Stage:Stage4.png

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalse"Healthy Beef": Fatty Acid Synthase Genetic Markers Associated with a Healthier Fatty Acid Compositionhttp://isurftech.technologypublisher.com/technology/19120Summary:
The amount of saturated and unsaturated fat in meat and dairy products is of significant interest because of their implications for human health, and in particular, the relationship between consumption of saturated fat and cholesterol levels.  ISU researchers have recently developed a genetic marker for identifying cattle that have a more healthful fatty acid composition.

Description:
Research has shown that human consumption of large amounts of saturated fats in foods such as meat can lead to heart disease.  ISU researchers investigating the bovine fatty acid synthase (FAS) gene have recently determined that the percentage of saturated fatty acids and the atherogenic index are associated with small genetic differences in the FAS gene.   Several single nucleotide polymorphisms (SNPs) were identified and a method was developed to identify these genetic markers.  This method has the potential to be a useful tool to genetically predict the fatty acid composition of beef or milk. In addition, the development of improved breeds could be accelerated since young animals can be tested before the meat or milk was harvested.

Advantage:
• Enables accelerated selection of cattle for “heart healthier” meat and dairy products compared to traditional breeding methods.

Application:
Rapid genetic selection of breeding stock with a lower atherogenic index and higher levels of healthier monounsaturated fatty acids

References:
Zhang, S., T. J. Knight, J. M. Reecy, and D. C. Beitz. 2008.  DNA polymorphisms in bovine fatty acid synthase are associated with beef fatty acid composition. Animal Genetics 39:62-70.

Development Stage:
Stage0.png
Commercial feasibility has been demonstrated, and  Iowa State University is seeking partners for non-exclusive licensing of this technology.

Desc0000.png


]]>Mon, 04 May 2015 06:51:32 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/191203499Mon, 13 Nov 2017 10:20:52 GMTSummary:

]]>Description:ISU researchers investigating the bovine fatty acid synthase (FAS) gene have recently determined that the percentage of saturated fatty acids and the atherogenic index are associated with small genetic differences in the FAS gene.   Several single nucleotide polymorphisms (SNPs) were identified and a method was developed to identify these genetic markers.  This method has the potential to be a useful tool to genetically predict the fatty acid composition of beef or milk. In addition, the development of improved breeds could be accelerated since young animals can be tested before the meat or milk was harvested.

]]>Advantage:]]>Application:

]]>References:Zhang, S., T. J. Knight, J. M. Reecy, and D. C. Beitz. 2008.  DNA polymorphisms in bovine fatty acid synthase are associated with beef fatty acid composition. Animal Genetics 39:62-70.

]]>Development Stage:Stage0.png

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life Sciences| Veterinary MedicineGenetic Markers in Fatty Acid Synthase for Identification of Meat Product Fatty Acid Content in CattleUtilityUnited States7,910,30812/177,4367/22/20083/22/20117/22/20285/4/201511/13/2017FalseImmunodeficient Pigs for Biomedical Researchhttp://isurftech.technologypublisher.com/technology/19191Summary:
Iowa State University researchers have identified pigs that have a severely impaired immune system that could serve as important biomedical model for the study of immune system and other diseases in humans.

Description:
Severe combined immunodeficiency (SCID) is a genetic defect that causes newborn animals to lack T or B cells in circulation and to have few or no lymphocytes in their primary or secondary lymphoid tissues.  SCID has been shown to have an autosomal recessive pattern of inheritance in certain mouse strains as well as in horses, some dog breeds, and humans, but is perhaps best known as the ‘bubble boy’ disease, which is an X-linked version of SCID in humans.  Affected neonates do not show clinical manifestations of the defect while suckling.  However, as maternal antibody wanes, the animals become susceptible to opportunistic infections to which they inexorably succumb. ISU researchers and their colleagues at Kansas State University have recently identified a SCID-like syndrome in a line of pigs originally bred for traits related to feed efficiency.  Because of the closer physiological resemblance between humans and pigs, these animals may have utility as a biomedical model for SCID and immunodeficiency diseases in humans that is more suitable than the current mouse models.  In addition, the anatomical and physiological similarities between humans and pigs would make these SCID pigs a superior biomedical model for research into cell and tissue transplantation, cancer research and efficacy of chemotherapeutics, as well as for testing new vaccines.

Advantage:
• More clinically relevant model for investigation of human immunodeficiency, cancer, and other diseases

Application:
Biomedical research

Group:
This technology is related to ISURF 4044: Genetic Basis and Test for Severe Combined Immune Deficiency in Pigs and related patent(s).

Development Stage:
Stage0.png
Matings that produced the affected pigs have been repeated and all litters have been confirmed to have at least one affected pig; genotyping analysis is in process.  ISU is seeking commercialization partners for these valuable research animals.

Desc0000.png

]]>Tue, 05 May 2015 10:38:58 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/191913992Mon, 13 Nov 2017 10:20:49 GMTSummary:

]]>Description:

]]>Advantage:]]>Application:]]>Group:ISURF 4044: Genetic Basis and Test for Severe Combined Immune Deficiency in Pigs and related patent(s).

]]>Development Stage:Stage0.png

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740FalseTrees for Woody Biomass Applications: Improved Cottonwoodshttp://isurftech.technologypublisher.com/technology/19681

Summary:
Eastern cottonwoods (Populus deltoides) that are suitable for planting in Iowa that produce increased biomass have been developed at Iowa State University.

Description:
Fast growing trees such as aspen, cottonwood, and eucalyptus can be grown as so-called short rotation crops, and have potential to be used as a source of woody biomass for the production of biofuels such as wood pellets and cellulosic ethanol.  In the prime cottonwood growing region, which includes eastern Louisiana, eastern Arkansas, western Mississippi and western Kentucky, cottonwoods can grow 12-15 feet per year, allowing them to be harvested biennially.   In addition, cottonwoods will regrow from stumps, so that plantings may be managed through coppicing. However, cottonwoods in the Great Plains are susceptible to melampsora leaf rust, which reduces their vigor.   Improved cottonwood (Populus deltoides) clones that produce increased biomass have been developed at Iowa State University.  These trees may facilitate the development of cottonwood plantations for biomass production in Iowa and similar climatic zones.

Advantage:
• The non-GMO cottonwood clone has increased woody density, improved winter hardiness, resistance to rust, and a high growth rate

Application:
Bioenergy; paper and pulp

References:
Tabor, G. M. et al. 2000. Bulked segregant analysis identifies molecular markers linked to Melamspora medusa resistance in Populus deltoides.  Phytopathology 90:1039-1042

Intellectual Property:
Tangible Material

Group:
This technology is related to ISURF #4157: Trees for Woody Biomass Applications: Improved Aspen Clones

Stage4.png
Development Stage:
The trees have been growing for several years and could be propogated by shoot or root cuttings

Desc0000.png

]]>Mon, 01 Jun 2015 11:49:52 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/196814156Mon, 13 Nov 2017 10:20:34 GMTSummary:

]]>Description:

]]>Advantage:Application:

]]>References:Tabor, G. M. et al. 2000. Bulked segregant analysis identifies molecular markers linked to Melamspora medusa resistance in Populus deltoides.  Phytopathology 90:1039-1042

]]>Intellectual Property:

]]>Group:ISURF #4157: Trees for Woody Biomass Applications: Improved Aspen Clones

]]>Stage4.pngDevelopment Stage:

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesFalseHoney Bee Feeding Inhibitorhttp://isurftech.technologypublisher.com/technology/19684Summary:
Iowa State University researchers developed a strategy for preventing honey bees from feeding on flowers on pesticide-treated plants that uses plant-based compounds as feeding deterrents.

Description:
The value of bee pollination has been estimated to be between $15 and $20 billion per year; however, the emergence of colony collapse disorder (CCD) in recent years as a significant problem affecting the health of honey bees poses a serious threat to the beekeeping and pollination industries.  CCD is also perceived as a serious threat to agriculture and food security since honey bees have become an integral tool for production of certain crops, particularly fruits and nuts.  CCD is still poorly understood at present, but environmental stressors such as exposure to pesticides at lethal or sub-lethal doses has been implicated as a cause. The lack of understanding of the mechanisms that contribute to CCD have also limited recommendations for its mitigation to best management practices for bee keepers,  and for the general public, to limiting honey bee exposure to pesticides through reducing usage, timing applications so that they are done when bees are not foraging, and planting pollinator-friendly plants.  To help address the need for better strategies to prevent or limit CCD, ISU researchers have identified a family of plant-based compounds that act as effective honey bee feeding deterrents.  These compounds may be combined with pesticides to prevent honey bees from foraging on plants that have recently been sprayed with insecticides, and thus may have utility for reducing honey bee exposure to potentially damaging chemicals.

Advantage:
• May deter honey bees from feeding on pesticide-treated plants
• Uses inexpensive, plant-based materials
• Non-GMO based

Application:
Crop production and protection

Development Stage :
Stage1.png
Pilot studies indicate that the antifeedants placed in nectar tubes in artificial flowers deter honey bees from feeding, and ISU is seeking partners for further development and commercialization of this technology.

Desc0000.png

]]>Mon, 01 Jun 2015 12:02:32 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/196844215Mon, 13 Nov 2017 10:20:29 GMTSummary:Iowa State University researchers developed a strategy for preventing honey bees from feeding on flowers on pesticide-treated plants that uses plant-based compounds as feeding deterrents.

]]>Description:The value of bee pollination has been estimated to be between $15 and $20 billion per year; however, the emergence of colony collapse disorder (CCD) in recent years as a significant problem affecting the health of honey bees poses a serious threat to the beekeeping and pollination industries.  CCD is also perceived as a serious threat to agriculture and food security since honey bees have become an integral tool for production of certain crops, particularly fruits and nuts.  CCD is still poorly understood at present, but environmental stressors such as exposure to pesticides at lethal or sub-lethal doses has been implicated as a cause. The lack of understanding of the mechanisms that contribute to CCD have also limited recommendations for its mitigation to best management practices for bee keepers,  and for the general public, to limiting honey bee exposure to pesticides through reducing usage, timing applications so that they are done when bees are not foraging, and planting pollinator-friendly plants.  To help address the need for better strategies to prevent or limit CCD, ISU researchers have identified a family of plant-based compounds that act as effective honey bee feeding deterrents.  These compounds may be combined with pesticides to prevent honey bees from foraging on plants that have recently been sprayed with insecticides, and thus may have utility for reducing honey bee exposure to potentially damaging chemicals.

]]>Advantage:May deter honey bees from feeding on pesticide-treated plants]]>Uses inexpensive, plant-based materials]]>• Non-GMO based]]>Application:Crop production and protection

]]>]]>]]>Pilot studies indicate that the antifeedants placed in nectar tubes in artificial flowers deter honey bees from feeding, and ISU is seeking partners for further development and commercialization of this technology.

]]>Desc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Agriculture| Life SciencesMethods and Compositions Comprising Steroid Honey Bee Feeding InhibitorsUtilityUnited States9,700,05215/137,0834/25/20167/11/20174/25/20367/17/201711/13/2017FalseNanoparticles Mediated Delivery of Nucleic Acids and Chemicals in Plantshttp://isurftech.technologypublisher.com/technology/19659Summary:
Gene delivery to plant cells is critical for understanding plant physiology and to develop new varieties with special traits.  ISU researchers have developed a novel method in plants useful for: 1) genetic transformation; 2) simultaneous delivery of nucleic acids and small molecules; and 3) controlled release of small molecules using appropriate induction reagents.

Description:
Current methods of plant genetic transformation include electroporation, polyethylene glycol or Agrobacterium tumefaciens-mediated transformation, or a bombardment approach using metal particles.  However, none of these techniques are able to provide simultaneous delivery of both nucleic acids (DNA or RNA) and chemicals or drugs to plant cells.  These methods also do not permit targeting of non-nuclear genomes (e.g., plastids or mitochondria) or sub-cellular compartments for delivery of nucleic acids and/or other compounds.  To overcome these drawbacks, ISU researchers have recently developed a method for plant genetic transformation using mesoporous silicate nanoparticles.  Because these hollow nanoparticles can be capped, controlled release and simultaneous delivery of nucleic acid and chemicals is possible.  In addition, modification of the nanoparticles with peptides or proteins can be used to direct their sub-cellular location through the cellular addressing machinery or other receptor-ligand interactions.  The utility of this method has been demonstrated using a green fluorescent protein reporter construct and tobacco plant cells.

Advantage:
• Enables simultaneous delivery of DNA and chemicals or small molecules
• Allows controlled release of nucleic acid and/or chemicals
• Targets both nuclear and non-nuclear (organelle) genomes

Application:
Transient and stable genetic transformation of plants. Simultaneous delivery of nucleic acids and small molecules for functional genomic studies. Controlled release of small molecules in planta using appropriate induction reagents.

References:
1: “A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent”, Radu, D.R., Lai, C.Y., Jeftinija, K., Rowe, E.W., Lin V.-S.  J. Am. Chem. Soc. (2004) 126, 13216-7.

Development Stage:
The utility of this method was demonstrated with tobacco mesophyll protoplasts and immature maize embryos.  ISU is seeking partners interested in commercializing this technology.

Stage0.png
Desc0000.png

]]>Mon, 01 Jun 2015 11:36:15 GMTlicensing@iastate.eduhttp://isurftech.technologypublisher.com/technology/196593383Mon, 13 Nov 2017 10:20:23 GMTSummary:Gene delivery to plant cells is critical for understanding plant physiology and to develop new varieties with special traits.  ISU researchers have developed a novel method in plants useful for: 1) genetic transformation; 2) simultaneous delivery of nucleic acids and small molecules; and 3) controlled release of small molecules using appropriate induction reagents.

]]>Description:

]]>Advantage:Enables simultaneous delivery of DNA and chemicals or small molecules]]>Allows controlled release of nucleic acid and/or chemicals]]>Targets both nuclear and non-nuclear (organelle) genomes]]>Application:Transient and stable genetic transformation of plants. Simultaneous delivery of nucleic acids and small molecules for functional genomic studies. Controlled release of small molecules in planta using appropriate induction reagents.

]]>References:1: “A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent”, Radu, D.R., Lai, C.Y., Jeftinija, K., Rowe, E.W., Lin V.-S.  J. Am. Chem. Soc. (2004) 126, 13216-7.

]]>Development Stage:The utility of this method was demonstrated with tobacco mesophyll protoplasts and immature maize embryos.  ISU is seeking partners interested in commercializing this technology.

]]>Stage0.pngDesc0000.pngDarioValenzuelaSenior Commercialization Manager, Life Sciencesdariov@iastate.edu515-294-4740Methods of Using Capped Mesoporous SilicatesUtilityUnited States8,647,64411/788,1474/19/20072/11/20144/19/20276/1/201511/13/2017False